| #1 | Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal gamma oscillations via upstream perforant path gating in Alzheimer's disease | SST | 0.968 | $0.60 | SDA-2026-04-03-26abc |
| #2 | GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance | GRIN2B | 0.964 | $0.57 | SDA-2026-04-03-26abc |
| #3 | Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to prevent tau propagation and restore entorhinal-hippocampal gamma synchrony in early Alzheimer's disease | SST | 0.955 | $0.58 | SDA-2026-04-03-26abc |
| #4 | Gamma entrainment therapy to restore hippocampal-cortical synchrony | SST | 0.946 | $0.60 | SDA-2026-04-03-26abc |
| #5 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Receptor Impairment | MAPT | 0.937 | $0.55 | SDA-2026-04-03-26abc |
| #6 | Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.924 | $0.69 | SDA-2026-04-01-gap-2 |
| #7 | APOE-Dependent Autophagy Restoration | MTOR | 0.895 | $0.67 | SDA-BIOMNI-SURVIVAL- |
| #8 | Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse | SLC16A1, SLC16A7, LDHA, PDHA1 | 0.895 | $0.59 | SDA-2026-04-26-gap-p |
| #9 | SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence | SIRT1 | 0.893 | $0.61 | SDA-2026-04-03-gap-a |
| #10 | TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration | TREM2 | 0.892 | $0.58 | SDA-2026-04-03-gap-a |
| #11 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia | ACSL4 | 0.891 | $0.59 | SDA-2026-04-03-gap-s |
| #12 | Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible | APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis) | 0.887 | $0.60 | SDA-2026-04-12-20260 |
| #13 | Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration | IFNG | 0.887 | $0.64 | SDA-2026-04-16-gap-d |
| #14 | TREM2-APOE Axis Dissociation for Selective DAM Activation | TREM2-APOE axis | 0.886 | $0.64 | SDA-2026-04-01-gap-0 |
| #15 | Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 palmitoylation stabilization | BDNF | 0.885 | $0.61 | SDA-2026-04-03-26abc |
| #16 | Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling for tau clearance | SST | 0.884 | $0.61 | SDA-2026-04-03-26abc |
| #17 | Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation | HCRTR1/HCRTR2 | 0.882 | $0.61 | sda-2026-04-01-gap-v |
| #18 | Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhythmogenesis and block tau AIS disruption in AD | PVALB | 0.869 | $0.60 | SDA-2026-04-03-26abc |
| #19 | Complement Cascade Inhibition Synaptic Protection | - | 0.867 | $0.58 | SDA-2026-04-26-gap-p |
| #20 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via direct PV interneuron recruitment in Alzheimer's disease | PVALB | 0.865 | $0.61 | SDA-2026-04-03-26abc |
| #21 | Glymphatic-Mediated Tau Clearance Dysfunction | MAPT | 0.865 | $0.60 | SDA-BIOMNI-PROTEOMI- |
| #22 | Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-gamma coupling and prevent tau seeding in AD | PVALB | 0.863 | $0.56 | SDA-2026-04-03-26abc |
| #23 | TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition | NAMPT | 0.862 | $0.66 | SDA-BIOMNI-VARIANT_- |
| #24 | TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance | TREM2 | 0.861 | $0.59 | SDA-2026-04-26-trem2 |
| #25 | Senescent Cell ASM-Complement Cascade Intervention | SMPD1 | 0.852 | $0.70 | SDA-2026-04-01-gap-l |
| #26 | Prime Editing Precision Correction of APOE4 to APOE3 in Microglia | APOE | 0.850 | $0.62 | SDA-2026-04-03-gap-c |
| #27 | TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection | TYROBP | 0.844 | $0.65 | SDA-BIOMNI-GENE_COE- |
| #28 | Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration | SMPD3 | 0.844 | $0.70 | SDA-2026-04-01-gap-l |
| #29 | miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Microglial State Transition | MIR155 | 0.843 | $0.64 | SDA-2026-04-16-gap-d |
| #30 | Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome | SST, SSTR1, SSTR2 | 0.839 | $0.58 | SDA-2026-04-26-gap-p |
| #31 | Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron-Ferroptosis-Edema Cascade Post-Cardiac Arrest | Labile iron pool (deferoxamine target) and GPX4 (sulforaphane target) | 0.838 | $0.60 | SDA-2026-04-26-gap-p |
| #32 | Gamma Oscillation Enhancement Synergy | - | 0.838 | $0.60 | SDA-2026-04-26-gap-p |
| #33 | Microglial Senescence Prevention via TREM2/SASP Axis | TREM2 | 0.837 | $0.58 | SDA-2026-04-26-gap-p |
| #34 | TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysregulation | TREM2/TYROBP | 0.836 | $0.66 | SDA-2026-04-06-gap-p |
| #35 | Differential Complement Regulator Expression on Synaptic Membranes (CD55/CD46) | CD55 (DAF), CD46 (MCP) | 0.833 | $0.64 | SDA-2026-04-07-gap-p |
| #36 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses | PRKAA1 | 0.833 | $0.73 | sda-2026-04-01-gap-v |
| #37 | IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface | IL6R, IL6 | 0.831 | $0.68 | SDA-2026-04-13-gap-p |
| #38 | Ketone Utilization Index as Metabolic Flexibility Biomarker | HMGCS2 | 0.829 | $0.57 | SDA-2026-04-04-gap-d |
| #39 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.827 | $0.61 | SDA-2026-04-03-26abc |
| #40 | Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal-prefrontal synchrony in early AD | SST | 0.827 | $0.56 | SDA-2026-04-03-26abc |
| #41 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymphatic enhancement and amyloid clearance from PV interneurons in Alzheimer's disease | PVALB | 0.827 | $0.56 | SDA-2026-04-03-26abc |
| #42 | miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy | miR-33/ABCA1 | 0.824 | $0.63 | SDA-2026-04-16-gap-d |
| #43 | Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD | AIM2, CASP1, IL1B, PYCARD, TARDBP | 0.824 | $0.67 | SDA-2026-04-01-gap-2 |
| #44 | SASP-Mediated Complement Cascade Amplification | C1Q/C3 | 0.822 | $0.61 | sda-2026-04-01-gap-0 |
| #45 | Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.822 | $0.60 | SDA-2026-04-01-gap-2 |
| #46 | STING Antagonists as ALS Therapeutics: Drug Repurposing | STING (TMEM173) | 0.821 | $0.62 | SDA-2026-04-07-gap-p |
| #47 | Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation | BDNF | 0.820 | $0.65 | SDA-2026-04-03-26abc |
| #48 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.814 | $0.61 | SDA-2026-04-04-gap-t |
| #49 | TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Restorative | TREM2 | 0.813 | $0.62 | SDA-2026-04-07-gap-p |
| #50 | CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerability Thresholds | APOE, CLU | 0.811 | $0.60 | SDA-2026-04-15-gap-d |
| #51 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.808 | $0.62 | SDA-2026-04-04-gap-t |
| #52 | CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion | CSF1R-TREM2 | 0.808 | $0.61 | SDA-2026-04-01-gap-0 |
| #53 | Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone Deficiency to Neuroinflammation | HCAR2 | 0.808 | $0.64 | SDA-2026-04-15-gap-d |
| #54 | Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin | CHI3L1/TREM2/NRGN | 0.807 | $0.62 | SDA-2026-04-06-gap-d |
| #55 | Neutrophil Extracellular Trap (NET) Inhibition | PADI4 | 0.806 | $0.69 | SDA-2026-04-16-gap-b |
| #56 | Mitochondrial DAMPs-Driven AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD | 0.805 | $0.63 | SDA-2026-04-01-gap-2 |
| #57 | Targeted Butyrate Supplementation for Microglial Phenotype Modulation | GPR109A | 0.805 | $0.58 | SDA-2026-04-01-gap-2 |
| #58 | Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD, PPIF | 0.804 | $0.60 | SDA-2026-04-01-gap-2 |
| #59 | TREM2-mTOR Co-Agonism for Metabolic Reprogramming | TREM2-mTOR pathway | 0.803 | $0.60 | SDA-2026-04-01-gap-0 |
| #60 | Dual-Receptor Antibody Shuttling | - | 0.803 | $0.60 | - |
| #61 | Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents Both Cytotoxic and Vasogenic Edema After Cardiac Arrest | AQP4 and ACSL4 (key ferroptosis regulator) | 0.803 | $0.62 | SDA-2026-04-26-gap-p |
| #62 | Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD | 0.803 | $0.59 | SDA-2026-04-01-gap-2 |
| #63 | 40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Disease-Associated Microglia | ACSL4 | 0.801 | $0.62 | SDA-2026-04-03-gap-s |
| #64 | Hypothesis 1: MANF/CDNF Signaling as Primary Neuroprotective Effector | MANF, CDNF | 0.798 | $0.59 | SDA-2026-04-26-gap-p |
| #65 | Microglial TREM2-SYK Pathway Enhancement | TREM2 | 0.798 | $0.59 | SDA-2026-04-03-gap-s |
| #66 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | APOE | 0.795 | $0.59 | sda-2026-04-01-gap-0 |
| #67 | Targeting SASP-Complement Amplification Through HIF-1α Downstream Effectors | C1QA, C1QB, C3, IL1B | 0.793 | $0.63 | SDA-2026-04-13-gap-p |
| #68 | Senescent Microglia Resolution via Maresins-Senolytics Combination | BCL2L1 | 0.791 | $0.59 | sda-2026-04-01-gap-0 |
| #69 | Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming | TLR4 | 0.789 | $0.68 | SDA-2026-04-01-gap-2 |
| #70 | VCP-Mediated Autophagy Enhancement | VCP | 0.787 | $0.59 | SDA-2026-04-04-gap-t |
| #71 | Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology | CHRNA7 (α7 nicotinic receptor), BACE1 | 0.785 | $0.60 | SDA-2026-04-12-20260 |
| #72 | Competitive APOE4 Domain Stabilization Peptides | APOE | 0.784 | $0.60 | sda-2026-04-01-gap-0 |
| #73 | Integrated Biomarker Panel for Therapeutic Window Identification | CHI3L1 | 0.784 | $0.59 | SDA-2026-04-15-gap-d |
| #74 | Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophagy flux and degrade intracellular tau before exosomal packaging in Alzheimer's disease | SST | 0.784 | $0.57 | SDA-2026-04-03-26abc |
| #75 | SASP-Driven Aquaporin-4 Dysregulation | AQP4 | 0.782 | $0.64 | sda-2026-04-01-gap-0 |
| #76 | Selective Acid Sphingomyelinase Modulation Therapy | SMPD1 | 0.782 | $0.65 | SDA-2026-04-01-gap-l |
| #77 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.780 | $0.59 | SDA-2026-04-04-gap-t |
| #78 | Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing Extracellular Tau Burden | AQP4, orexin receptor (HCRTR1/2) | 0.780 | $0.63 | SDA-2026-04-06-gap-d |
| #79 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease | ACSL4 | 0.779 | $0.58 | SDA-2026-04-03-gap-s |
| #80 | PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes | PDE4A, PDE4B, PDE4D | 0.779 | $0.62 | SDA-2026-04-13-gap-p |
| #81 | Selective HDAC3 Inhibition with Cognitive Enhancement | HDAC3 | 0.779 | $0.71 | SDA-2026-04-04-gap-e |
| #82 | SIRT1/PGC-1α Axis Activation to Preserve Mitochondrial Resiliency Against Microbiome-Induced Neuroinflammation in PD | SIRT1, PGC-1α (PPARGC1A), NAMPT | 0.778 | $0.60 | SDA-BIOMNI-MICROBIO- |
| #83 | LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine in Disease-Associated Microglia | LPCAT3 | 0.777 | $0.57 | SDA-2026-04-03-gap-s |
| #84 | CX3CR1-TREM2 Integration for Synapse Pruning Normalization | CX3CR1-TREM2 | 0.776 | $0.60 | SDA-2026-04-01-gap-0 |
| #85 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia | LPCAT3 | 0.776 | $0.55 | SDA-2026-04-03-gap-s |
| #86 | Prefrontal sensory gating circuit restoration via PV interneuron enhancement | PVALB | 0.775 | $0.65 | SDA-2026-04-03-26abc |
| #87 | Dual-Circuit Tau Vulnerability Cascade | MAPT | 0.774 | $0.57 | SDA-2026-04-03-26abc |
| #88 | TREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid Sensing and Clearance Deficits | TREM2, APOE | 0.774 | $0.62 | SDA-2026-04-02-gap-0 |
| #89 | Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation | FCGRT | 0.773 | $0.58 | sda-2026-04-01-gap-0 |
| #90 | ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE Peroxidation | ALOX15 | 0.772 | $0.57 | SDA-2026-04-03-gap-s |
| #91 | Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway | GPNMB, CD44 | 0.772 | $0.60 | SDA-2026-04-26-gap-p |
| #92 | Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation | TREM2 | 0.771 | $0.61 | SDA-2026-04-04-gap-t |
| #93 | Oligodendrocyte Precursor Cell Senescence in White Matter Disease | CSPG4,OLIG2,BCL2 | 0.769 | $0.57 | SDA-2026-04-04-gap-s |
| #94 | Chromatin Accessibility Restoration via BRD4 Modulation | BRD4 | 0.768 | $0.60 | SDA-2026-04-04-gap-e |
| #95 | CYP46A1 Overexpression Gene Therapy | CYP46A1 | 0.768 | $0.65 | SDA-2026-04-01-gap-l |
| #96 | AAV-PHP.eB-Mediated Microglial IGFBPL1 Expression | IGFBPL1 | 0.768 | $0.61 | SDA-2026-04-06-gap-d |
| #97 | Lysosomal Cathepsin-Dependent Tau Clearance | - | 0.767 | $0.62 | SDA-2026-04-26-gap-p |
| #98 | APOE4 Allosteric Rescue via Small Molecule Chaperones | APOE | 0.765 | $0.60 | sda-2026-04-01-gap-0 |
| #99 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Microglia | LPCAT3 | 0.764 | $0.61 | SDA-2026-04-03-gap-s |
| #100 | Selective LXRβ agonists restore ABCA1/ABCG1 expression and APOE lipidation in APOE4 astrocytes, normalizing cholesterol export and reducing AD-relevant neurotoxicity | NR1H2 (LXRβ), ABCA1, ABCG1 | 0.763 | $0.61 | SDA-2026-04-04-gap-a |
| #101 | SASP-Mediated Cholinergic Synapse Disruption | MMP2/MMP9 | 0.763 | $0.63 | sda-2026-04-01-gap-0 |
| #102 | Circadian Clock-Autophagy Synchronization | CLOCK | 0.763 | $0.59 | sda-2026-04-01-gap-v |
| #103 | Hypothesis 3: HepaCAM-Containing Extracellular Vesicles | HEPACAM1, HEPACAM2 | 0.762 | $0.59 | SDA-2026-04-26-gap-p |
| #104 | TREM2 Crosstalk and Synergistic Activation of Phagocytic Transcriptome | TREM2/DAP12 (TYROBP) | 0.761 | $0.61 | SDA-2026-04-06-gap-p |
| #105 | Cell-Type Specific TREM2 Upregulation in DAM Microglia | TREM2 | 0.761 | $0.57 | analysis-SEAAD-20260 |
| #106 | cGAS-STING Pathway Hyperactivation Mediates Tau Propagation | cGAS (CGAS), STING (TMEM173) | 0.760 | $0.62 | SDA-2026-04-02-gap-2 |
| #107 | Targeted APOE4-to-APOE3 Base Editing Therapy | APOE | 0.758 | $0.64 | sda-2026-04-01-gap-0 |
| #108 | INPP5D (SHIP1) Inhibition to Shift Microglial Polarization | INPP5D | 0.758 | $0.60 | SDA-2026-04-01-gap-0 |
| #109 | APOE4 astrocytes exhibit impaired cholesterol efflux via ABCA1/ABCG1 transporters, driving intracellular lipid droplet accumulation and secondary neuronal cholesterol deficiency | ABCA1, ABCG1 | 0.758 | $0.62 | SDA-2026-04-04-gap-a |
| #110 | sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy | TREM2 | 0.757 | $0.68 | SDA-2026-04-26-gap-p |
| #111 | Multi-Modal Stress Response Harmonization | NR3C1/CRH/TNFA | 0.756 | $0.57 | sda-2026-04-01-gap-0 |
| #112 | Senescence-Activated NAD+ Depletion Rescue | CD38/NAMPT | 0.755 | $0.57 | sda-2026-04-01-gap-0 |
| #113 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.755 | $0.59 | test-hypothesis-fixt |
| #114 | GFAP-Positive Reactive Astrocyte Subtype Delineation | GFAP | 0.754 | $0.59 | analysis-SEAAD-20260 |
| #115 | Temporal SPP1 Inhibition During Critical Windows | SPP1 | 0.752 | $0.67 | SDA-2026-04-15-gap-p |
| #116 | Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and restore perforant-path gamma gating in AD | SST | 0.752 | $0.65 | SDA-2026-04-03-26abc |
| #117 | TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming | TREM2, CSF1R | 0.748 | $0.61 | SDA-2026-04-03-gap-a |
| #118 | Closed-loop focused ultrasound targeting EC-II SST interneurons to restore gamma gating and block tau propagation in AD | SST | 0.748 | $0.63 | SDA-2026-04-03-26abc |
| #119 | C1QA/C1QB Subunit-Specific Inhibition to Block Aberrant PV Interneuron Input Elimination in Alzheimer's Disease | C1QA, C1QB | 0.747 | $0.60 | SDA-2026-04-15-gap-d |
| #120 | Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Overexpression | NAMPT | 0.745 | $0.62 | SDA-2026-04-04-gap-e |
| #121 | Circadian-Synchronized Proteostasis Enhancement | CLOCK/ULK1 | 0.744 | $0.57 | sda-2026-04-01-gap-0 |
| #122 | TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging | TREM2 | 0.744 | $0.62 | SDA-2026-04-03-gap-a |
| #123 | APOE Isoform Expression Across Glial Subtypes | APOE | 0.743 | $0.60 | analysis-SEAAD-20260 |
| #124 | Peripheral Monocyte/Macrophage Infiltration Mimicking Microglial Loss | CCR2 | 0.743 | $0.61 | SDA-2026-04-07-gap-p |
| #125 | Smartphone-Detected Motor Variability Correction | DRD2/SNCA | 0.742 | $0.58 | sda-2026-04-01-gap-0 |
| #126 | Senescent Cell Mitochondrial DNA Release | CGAS/STING1/DNASE2 | 0.742 | $0.58 | sda-2026-04-01-gap-0 |
| #127 | Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement | COX4I1 | 0.742 | $0.59 | sda-2026-04-01-gap-v |
| #128 | APOE4-Selective Lipid Nanoemulsion Therapy | APOE | 0.742 | $0.58 | sda-2026-04-01-gap-a |
| #129 | APOE-TREM2 Interaction Modulation | TREM2 | 0.741 | $0.58 | sda-2026-04-01-gap-a |
| #130 | Complement-SASP Amplification Cascade as Mechanistic Link | C1QA, C1QB, C3, IL1B, NFKB1 | 0.741 | $0.59 | SDA-2026-04-16-gap-p |
| #131 | Epigenetic Memory Erasure via TET2 Activation | TET2 | 0.741 | $0.58 | sda-2026-04-01-gap-0 |
| #132 | PARP1 Inhibition Therapy | PARP1 | 0.738 | $0.63 | sda-2026-04-01-gap-0 |
| #133 | Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determines AQP4 Tolerance Fate | AHR, IL10, TNFRSF13B, TIGIT, FOXP3 | 0.738 | $0.55 | SDA-2026-04-13-gap-p |
| #134 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction | SIRT3 | 0.738 | $0.57 | SDA-2026-04-03-gap-s |
| #135 | TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies | TREM2, TYROBP (DAP12), PLCG2, SYK | 0.735 | $0.59 | SDA-2026-04-16-gap-p |
| #136 | Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Antagonist in Tau Phase | TREM2, APOE, MAPT | 0.735 | $0.58 | SDA-2026-04-02-gap-0 |
| #137 | Metabolic Inflexibility Precedes Transcriptional Reprogramming (NAD+/SIRT3 Axis) | SIRT3/NAD+ salvage pathway, PGC-1α | 0.735 | $0.58 | SDA-2026-04-06-gap-d |
| #138 | SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Lysosome Fusion Dysfunction | SGMS1, BECN1 | 0.734 | $0.60 | SDA-2026-04-15-gap-p |
| #139 | Aquaporin-4 Polarization Rescue | AQP4 | 0.732 | $0.60 | sda-2026-04-01-gap-0 |
| #140 | Senescence-Associated Myelin Lipid Remodeling | PLA2G6/PLA2G4A | 0.732 | $0.55 | sda-2026-04-01-gap-0 |
| #141 | Selective Neutral Sphingomyelinase-2 Inhibition Therapy | SMPD3 | 0.731 | $0.59 | SDA-2026-04-01-gap-l |
| #142 | Senescence-Induced Lipid Peroxidation Spreading | GPX4/SLC7A11 | 0.730 | $0.58 | sda-2026-04-01-gap-0 |
| #143 | Adenosine-Astrocyte Metabolic Reset | ADORA2A | 0.730 | $0.58 | sda-2026-04-01-gap-v |
| #144 | Phase-Separated Organelle Targeting | G3BP1 | 0.729 | $0.60 | sda-2026-04-01-gap-0 |
| #145 | Synthetic Biology BBB Endothelial Cell Reprogramming | TFR1, LRP1, CAV1, ABCB1 | 0.727 | $0.57 | sda-2026-04-01-gap-0 |
| #146 | Metabolic Switch Targeting for A1→A2 Repolarization | HK2 | 0.726 | $0.57 | sda-2026-04-01-gap-0 |
| #147 | Microglial TREM2-Complement Axis Modulation | TREM2 and C3 | 0.726 | $0.60 | SDA-2026-04-03-gap-s |
| #148 | TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking | TFAM | 0.725 | $0.59 | sda-2026-04-01-gap-v |
| #149 | Astrocyte-Mediated Neuronal Epigenetic Rescue | HDAC | 0.725 | $0.57 | SDA-2026-04-04-gap-e |
| #150 | Proteostasis Enhancement via APOE Chaperone Targeting | HSPA1A | 0.724 | $0.57 | sda-2026-04-01-gap-a |
| #151 | TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I IFN Hyperactivation | TBK1 | 0.724 | $0.60 | SDA-2026-04-13-gap-p |
| #152 | CSF YKL-40 as a Priming-Specific Chitinase Marker | CHI3L1/YKL-40 | 0.723 | $0.56 | SDA-2026-04-06-gap-d |
| #153 | Interfacial Lipid Mimetics to Disrupt Domain Interaction | APOE | 0.723 | $0.58 | sda-2026-04-01-gap-0 |
| #154 | Circadian Rhythm Entrainment of Reactive Astrocytes | BMAL1 | 0.722 | $0.57 | sda-2026-04-01-gap-0 |
| #155 | Regional TREM2-Dependent Lipid Metabolism Determines Cortical Vulnerability in Alzheimer's Disease | TREM2 | 0.721 | $0.60 | SDA-2026-04-06-gap-p |
| #156 | Sleep Spindle-Synaptic Plasticity Enhancement | CACNA1G | 0.721 | $0.57 | sda-2026-04-01-gap-v |
| #157 | Excessive C1q/C3/CR3 complement cascade activation initiates pre-symptomatic synaptic loss in Alzheimer's disease | C1QA, C1QB, C1QC, C3, ITGAM/ITGAX | 0.720 | $0.60 | SDA-2026-04-02-gap-s |
| #158 | H3: APOE4 Impairs Cholesterol Trafficking, Triggering Astrocyte Senescence | ABCA1/ABCG1; LXR (NR1H3) | 0.720 | $0.60 | SDA-2026-04-06-gap-d |
| #159 | SASP Secretome-based Molecular Distinction via CXCL1/CXCL2/MMP-3 Ratio | CXCL1, CXCL2, MMP3 | 0.720 | $0.60 | SDA-2026-04-06-gap-d |
| #160 | Metabolic Reprogramming to Reverse Senescence | SIRT1,PGC1A,NAMPT | 0.720 | $0.61 | SDA-2026-04-04-gap-s |
| #161 | Microglial IFN-β Priming of Motor Neuron cGAS/STING Amplification | IFNAR1/IFNAR2, STING (TMEM173), cGAS (CGAS) | 0.720 | $0.61 | SDA-2026-04-07-gap-p |
| #162 | NLRP3 Inflammasome Lock Perpetuates Senescence-Associated Inflammasome Phenotype | NLRP3/CASP1/IL1B | 0.720 | $0.60 | SDA-2026-04-06-gap-p |
| #163 | Stress Granule Phase Separation Modulators | G3BP1 | 0.720 | $0.67 | sda-2026-04-01-gap-v |
| #164 | Magnetosonic-Triggered Transferrin Receptor Clustering | TFR1 | 0.719 | $0.57 | sda-2026-04-01-gap-0 |
| #165 | Retinal Vascular Microcirculation Rescue | PDGFRB/ANGPT1 | 0.718 | $0.57 | sda-2026-04-01-gap-0 |
| #166 | TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR Axis for Microglial Metabolic Fitness | TREM2, TYROBP, SYK, PI3K | 0.718 | $0.58 | SDA-2026-04-02-gap-0 |
| #167 | APOE Isoform Conversion Therapy | APOE | 0.718 | $0.59 | sda-2026-04-01-gap-a |
| #168 | Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | APOE, LRP1, LDLR | 0.718 | $0.57 | sda-2026-04-01-gap-0 |
| #169 | TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration | TREM2 | 0.716 | $0.60 | SDA-2026-04-26-trem2 |
| #170 | Circadian-Synchronized LRP1 Pathway Activation | LRP1, MTNR1A, MTNR1B | 0.714 | $0.56 | sda-2026-04-01-gap-0 |
| #171 | Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis from Inflammation | TREM2, ADAM10, ADAM17 | 0.714 | $0.59 | SDA-2026-04-02-gap-0 |
| #172 | Purinergic Signaling Polarization Control | P2RY1 and P2RX7 | 0.713 | $0.58 | sda-2026-04-01-gap-0 |
| #173 | TREM2-ASM Crosstalk in Microglial Lysosomal Senescence | SMPD1 | 0.713 | $0.61 | SDA-2026-04-03-gap-a |
| #174 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.712 | $0.59 | test-hypothesis-fixt |
| #175 | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | MTNR1A | 0.712 | $0.56 | sda-2026-04-01-gap-v |
| #176 | Early Proteasome Restoration Therapy | PSMC | 0.712 | $0.56 | SDA-2026-04-03-gap-a |
| #177 | Noradrenergic-Tau Propagation Blockade | ADRA2A | 0.711 | $0.59 | sda-2026-04-01-gap-v |
| #178 | APOE4-Specific Microglial Metabolic Rescue | APOE, ABCA1, LDLR | 0.710 | $0.60 | SDA-2026-04-04-gap-n |
| #179 | HDAC3-Selective Inhibition for Clock Reset | HDAC3 | 0.710 | $0.58 | sda-2026-04-01-gap-v |
| #180 | Microglial Disease-Associated States: TREM2-Independent Pathways Driving Neuroinflammation | APOE | 0.710 | $0.60 | SDA-2026-04-02-gap-s |
| #181 | H4: Senomorphic Compounds Preserve Astrocyte Function While Reversing Senescence | MTOR; MEGF10; MERTK | 0.710 | $0.60 | SDA-2026-04-06-gap-d |
| #182 | Metabolic Circuit Breaker via Lipid Droplet Modulation | PLIN2 | 0.709 | $0.60 | sda-2026-04-01-gap-0 |
| #183 | Autophagosome Maturation Checkpoint Control | STX17 | 0.709 | $0.60 | sda-2026-04-01-gap-0 |
| #184 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | LOX/LOXL1-4 | 0.709 | $0.59 | sda-2026-04-01-gap-v |
| #185 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.708 | $0.64 | SDA-2026-04-03-gap-a |
| #186 | Membrane Cholesterol Gradient Modulators | ABCA1/LDLR/SREBF2 | 0.708 | $0.59 | SDA-2026-04-01-gap-l |
| #187 | Orexin-Microglia Modulation Therapy | HCRTR2 | 0.707 | $0.60 | sda-2026-04-01-gap-v |
| #188 | Creatine Kinase System Capacity as Neural Energy Reserve Biomarker | CKB | 0.707 | $0.58 | SDA-2026-04-04-gap-d |
| #189 | TET2-Mediated Demethylation Rejuvenation Therapy | TET2 | 0.706 | $0.56 | sda-2026-04-01-gap-v |
| #190 | Lysosomal Enzyme Trafficking Correction | IGF2R | 0.706 | $0.60 | sda-2026-04-01-gap-0 |
| #191 | Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation | SDC1 | 0.705 | $0.58 | sda-2026-04-01-gap-v |
| #192 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.705 | $0.64 | test-hypothesis-fixt |
| #193 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | GPX4 | 0.705 | $0.57 | SDA-2026-04-03-gap-a |
| #194 | Microglial Efferocytosis Enhancement via GPR32 Superagonists | CMKLR1 | 0.704 | $0.56 | sda-2026-04-01-gap-0 |
| #195 | Astrocyte-Neuron Metabolic Coupling Titration | BDH1 | 0.704 | $0.59 | SDA-2026-04-03-gap-d |
| #196 | TLR4/MyD88/NF-κB Axis Blockade to Interrupt LPS-Mediated Gut-Brain Neuroinflammation in PD | TLR4, MyD88 (MYD88), NF-κB (NFKB1) | 0.703 | $0.60 | SDA-2026-04-16-gap-2 |
| #197 | Purinergic P2Y12 Inverse Agonist Therapy | P2RY12 | 0.703 | $0.57 | sda-2026-04-01-gap-v |
| #198 | Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration | SIRT3 | 0.701 | $0.55 | SDA-2026-04-04-gap-e |
| #199 | DAMP-Scavenging Microglial Reset | HMGB1, S100 proteins | 0.701 | $0.58 | SDA-2026-04-04-gap-n |
| #200 | Microglial Purinergic Reprogramming | P2RY12 | 0.701 | $0.56 | sda-2026-04-01-gap-0 |
| #201 | Nutrient-Sensing Epigenetic Circuit Reactivation | SIRT1 | 0.700 | $0.63 | SDA-2026-04-04-gap-e |
| #202 | TREM2 haploinsufficiency dysregulates microglial synaptic surveillance, switching from protective 'disease-associated microglia' to neurotoxic 'inflammasome-active' states | TREM2, TYROBP (DAP12), APOE | 0.700 | $0.59 | SDA-2026-04-02-gap-s |
| #203 | SCFA-Producing Bacterial Depletion → Loss of Neuroprotective Microenvironment | HDAC3, GPR41 (FFAR3), GPR43 (FFAR2), Nrf2, HMOX1 | 0.700 | $0.60 | sda-2026-04-01-gap-2 |
| #204 | Metabolic Coupling Disruption Sensitizes Motor Neuron mPTP Threshold | PDH (pyruvate dehydrogenase), MCT1/2, PDK, mPTP (ANT/VDAC/Cyclophilin D) | 0.700 | $0.59 | SDA-2026-04-07-gap-p |
| #205 | NAD+ Decline and SIRT1 Deficiency Drive Epigenetic Reprogramming Toward Senescence | SIRT1/NAMPT/PPARGC1A | 0.700 | $0.59 | SDA-2026-04-06-gap-p |
| #206 | AAV-Mediated APOE2/APOE3 Gene Delivery to Convert APOE Genotype | APOE | 0.700 | $0.60 | SDA-2026-04-02-gap-a |
| #207 | Mechanosensitive Ion Channel Reprogramming | PIEZO1 and KCNK2 | 0.700 | $0.57 | sda-2026-04-01-gap-0 |
| #208 | H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector | PXR (NR1I2), IDO1 | 0.699 | $0.64 | SDA-2026-04-15-gap-p |
| #209 | Granzyme B Inhibition with Serpina3n to Preserve Axonal Integrity Against Cytotoxic Attack | GZMB | 0.698 | $0.60 | SDA-2026-04-15-gap-d |
| #210 | Microglial P2Y12-Dependent Territorial Segregation of Synaptic Inputs | P2RY12 (P2Y12 receptor) | 0.697 | $0.60 | SDA-2026-04-07-gap-p |
| #211 | TFEB-Independent Autophagy Bypass | ULK1 | 0.697 | $0.56 | SDA-2026-04-03-gap-d |
| #212 | Lysosomal Calcium Channel Modulation Therapy | MCOLN1 | 0.697 | $0.58 | sda-2026-04-01-gap-0 |
| #213 | Perforant Path Presynaptic Terminal Protection Strategy | PPARGC1A | 0.696 | $0.57 | sda-2026-04-01-gap-0 |
| #214 | Axonal RNA Transport Reconstitution | HNRNPA2B1 | 0.695 | $0.58 | sda-2026-04-01-gap-v |
| #215 | Mitochondrial Transfer Pathway Enhancement | MIRO1 | 0.695 | $0.57 | sda-2026-04-01-gap-0 |
| #216 | Temporal Microglial State Switching | Optogenetic constructs, ion channels | 0.695 | $0.58 | SDA-2026-04-04-gap-n |
| #217 | Complement C1q Mimetic Decoy Therapy | C1QA | 0.695 | $0.57 | sda-2026-04-01-gap-v |
| #218 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | ALOX15 | 0.695 | $0.56 | sda-2026-04-01-gap-0 |
| #219 | Palmitoylation-Targeted BACE1 Trafficking Disruptors | BACE1 | 0.693 | $0.55 | SDA-2026-04-01-gap-l |
| #220 | Ocular Immune Privilege Extension | FOXP3/TGFB1 | 0.692 | $0.56 | sda-2026-04-01-gap-0 |
| #221 | Sphingomyelin Synthase Activators for Raft Remodeling | SGMS1/SGMS2 | 0.692 | $0.56 | SDA-2026-04-01-gap-l |
| #222 | cGAS-STING Senescence Circuit Disruption | CGAS, STING1 | 0.691 | $0.58 | SDA-2026-04-03-gap-a |
| #223 | Extracellular Matrix Stiffness Modulation | PIEZO1 | 0.691 | $0.56 | sda-2026-04-01-gap-0 |
| #224 | H5: BET Bromodomain Readers Sense Aberrant Chromatin and Drive Neuroinflammatory Transcription | BRD4, BET bromodomains (BRD2/3/4) | 0.690 | $0.59 | SDA-2026-04-04-gap-2 |
| #225 | Rab27A/B-mediated exosomal tau secretion from microglia drives frontal cortex propagation at Braak III-VI | RAB27A | 0.690 | $0.59 | SDA-2026-04-07-gap-d |
| #226 | TREM2 Agonism to Rescue APOE4-Induced Microglial Dysfunction | TREM2 | 0.690 | $0.60 | SDA-2026-04-02-gap-a |
| #227 | Astrocyte Reactivity Heterogeneity with APOE4-Dependent Vulnerability | APOE | 0.690 | $0.59 | SDA-2026-04-02-gap-s |
| #228 | Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurodegeneration in FTD-GRN | GRN, SLC16A3 (MCT4) | 0.690 | $0.60 | SDA-2026-04-02-gap-2 |
| #229 | Loss of AQP4 Polarization Impairs Glymphatic Perivascular Influx, Causing Metabolite Accumulation | AQP4 | 0.690 | $0.59 | SDA-2026-04-07-gap-p |
| #230 | TREM2-Dependent Microglial State Transition as Therapeutic Window in Alzheimer's Disease | TREM2, SYK signaling pathway | 0.690 | $0.59 | SDA-2026-04-02-gap-2 |
| #231 | Ganglioside Rebalancing Therapy | ST3GAL2/ST8SIA1 | 0.690 | $0.54 | SDA-2026-04-01-gap-l |
| #232 | CSF Soluble TREM2 Fragment Ratio as Priming State Indicator | TREM2/ADAM10/17 | 0.689 | $0.59 | SDA-2026-04-06-gap-d |
| #233 | Endothelial NRF2 Activation as a Master Switch for Post-CA BBB Protection | NRF2 (NFE2L2) in brain microvascular endothelial cells | 0.689 | $0.62 | SDA-2026-04-26-gap-p |
| #234 | Reelin-Mediated Cytoskeletal Stabilization Protocol | RELN | 0.689 | $0.58 | sda-2026-04-01-gap-0 |
| #235 | Cross-Seeding Prevention Strategy | TARDBP | 0.689 | $0.58 | sda-2026-04-01-gap-v |
| #236 | Hypocretin-Neurogenesis Coupling Therapy | HCRT | 0.688 | $0.57 | sda-2026-04-01-gap-v |
| #237 | Lysosomal Positioning Dynamics Modulation | LAMP1 | 0.686 | $0.56 | sda-2026-04-01-gap-0 |
| #238 | TREM2 Conformational Stabilizers for Synaptic Discrimination | TREM2 | 0.685 | $0.57 | sda-2026-04-01-gap-v |
| #239 | Pericyte Contractility Reset via Selective PDGFR-β Agonism | PDGFRB | 0.684 | $0.55 | sda-2026-04-01-gap-v |
| #240 | Focused Ultrasound with Microbubble Contrast Agents | IGFBPL1 | 0.684 | $0.60 | SDA-2026-04-06-gap-d |
| #241 | Astrocyte-Selective APOE4 Silencing via Lipid Nanoparticles | APOE4 | 0.682 | $0.58 | SDA-2026-04-03-gap-d |
| #242 | Context-Dependent CRISPR Activation in Specific Neuronal Subtypes | Cell-type-specific essential genes | 0.682 | $0.55 | SDA-2026-04-03-gap-c |
| #243 | Flotillin-1 Stabilization Compounds | FLOT1 | 0.681 | $0.54 | SDA-2026-04-01-gap-l |
| #244 | Autophagy-Lysosomal Degradation of IBA1 in Stressed Microglia | LC3/P62/SQSTM1 | 0.681 | $0.58 | SDA-2026-04-07-gap-p |
| #245 | CRISPR-Mediated Mitochondrial Genome Editing for Complex I Dysfunction | MT-ND1, MT-ND4, MT-ND6 | 0.681 | $0.56 | SDA-2026-04-03-gap-c |
| #246 | NLRP3/Mitophagy Coupling Modulation | NLRP3 | 0.681 | $0.57 | SDA-2026-04-03-gap-i |
| #247 | TREM2 R47H variant synergizes with APOE4 to collapse microglial lipid clearance capacity, causing extracellular lipid accumulation that feeds back to astrocyte lipid droplet formation | TREM2, APOE | 0.681 | $0.60 | SDA-2026-04-04-gap-a |
| #248 | R-Loop Resolution Enhancement Therapy | SETX | 0.680 | $0.56 | sda-2026-04-01-gap-v |
| #249 | Chaperone-Mediated APOE4 Refolding Enhancement | HSPA1A, HSP90AA1, DNAJB1, FKBP5 | 0.680 | $0.56 | sda-2026-04-01-gap-0 |
| #250 | Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus | AQP1 | 0.680 | $0.55 | sda-2026-04-01-gap-v |
| #251 | Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution | GPR37 | 0.680 | $0.56 | sda-2026-04-01-gap-0 |
| #252 | AQP4 Dysregulation Promotes Neuroinflammation Through Impaired CNS-Peripheral Immune Interface Function | AQP4; IL6R; CD46 (complement) | 0.680 | $0.59 | SDA-2026-04-07-gap-p |
| #253 | Glial Neuroinflammatory Amplification by TDP-43 Pathology | TARDBP | 0.680 | $0.59 | SDA-2026-04-08-gap-p |
| #254 | ... | ... | 0.680 | $0.54 | SDA-2026-04-02-gap-a |
| #255 | GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade | GPX4 | 0.680 | $0.58 | SDA-2026-04-16-gap-f |
| #256 | Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation | GJA1 | 0.679 | $0.52 | SDA-2026-04-01-gap-2 |
| #257 | Complement C1QA Spatial Gradient in Cortical Layers | C1QA | 0.678 | $0.55 | analysis-SEAAD-20260 |
| #258 | Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification Biomarker | SLC16A1 | 0.677 | $0.54 | SDA-2026-04-04-gap-d |
| #259 | Cell-Type Specific TFEB Modulation | TFEB | 0.677 | $0.58 | SDA-2026-04-03-gap-d |
| #260 | Astrocyte-Mediated Microglial Memory Erasure | GFAP, S100B | 0.677 | $0.57 | SDA-2026-04-04-gap-n |
| #261 | Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes | MAPT | 0.676 | $0.57 | SDA-2026-04-03-gap-s |
| #262 | Microglial TREM2-Mediated Tau Phagocytosis Impairment | MAPT | 0.676 | $0.57 | SDA-2026-04-03-26abc |
| #263 | White Matter Oligodendrocyte Protection via CXCL10 Inhibition | CXCL10 | 0.675 | $0.58 | SDA-2026-04-03-gap-a |
| #264 | Excitatory Neuron Vulnerability via SLC17A7 Downregulation | SLC17A7 | 0.675 | $0.56 | analysis-SEAAD-20260 |
| #265 | RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery | RAB27A | 0.674 | $0.53 | sda-2026-04-01-gap-v |
| #266 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | HK2 | 0.672 | $0.56 | sda-2026-04-01-gap-v |
| #267 | Astrocytic-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.672 | $0.57 | SDA-2026-04-03-26abc |
| #268 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | OCT4 | 0.672 | $0.56 | SDA-2026-04-04-gap-e |
| #269 | AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Neuronal Death via Dysfunction of the Glutamate-Gln Cycle | AQP4; SLC1A2 (GLT-1) | 0.670 | $0.58 | SDA-2026-04-07-gap-p |
| #270 | Restore AQP4 Perivascular Polarization by Stabilizing DAPC/SNTA1/DAG1 Anchoring Complex | AQP4, SNTA1, DAG1 | 0.670 | $0.59 | SDA-2026-04-07-gap-p |
| #271 | LPS-primed microglial trained immunity establishes persistent H3K4me3 landscapes at complement gene loci, driving hyperactive synaptic pruning in late-life neurodegeneration | NLRP3, H3K4me3 writers (MLL3/4, SETD1A), H3K27ac (EP300/CREBBP) | 0.670 | $0.59 | SDA-2026-04-02-gap-s |
| #272 | TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation | TREM2/ACAT1/LXR | 0.670 | $0.58 | SDA-2026-04-15-gap-d |
| #273 | Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication | CHRNA7 | 0.669 | $0.55 | SDA-2026-04-01-gap-2 |
| #274 | Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling | SLC16A1 | 0.668 | $0.55 | SDA-2026-04-03-gap-s |
| #275 | Locus Coeruleus-Hippocampal Circuit Protection | MAPT | 0.668 | $0.56 | SDA-2026-04-03-26abc |
| #276 | TREM2 Agonism Has Narrow Early-Window at DAM1→DAM2 Transition Checkpoint | TREM2, SYK signaling axis | 0.668 | $0.58 | SDA-2026-04-06-gap-d |
| #277 | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | KCNK2 | 0.668 | $0.55 | sda-2026-04-01-gap-v |
| #278 | Mitochondrial-Lysosomal Contact Site Engineering | RAB7A | 0.668 | $0.55 | sda-2026-04-01-gap-0 |
| #279 | White Matter Vulnerability Prevention via Oligodendrocyte Protection | CXCL10 | 0.667 | $0.57 | SDA-2026-04-03-gap-a |
| #280 | TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence | CYP46A1 | 0.666 | $0.59 | SDA-2026-04-03-gap-a |
| #281 | Lipid Droplet Dynamics as Phenotype Switches | DGAT1 and SOAT1 | 0.666 | $0.56 | sda-2026-04-01-gap-0 |
| #282 | GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer | GAP43 | 0.666 | $0.57 | sda-2026-04-01-gap-v |
| #283 | Glymphatic-Cholinergic Tau Clearance Cascade | MAPT | 0.666 | $0.56 | SDA-2026-04-03-26abc |
| #284 | Oligodendrocyte DNA Repair Enhancement Therapy | PARP1 and XRCC1 | 0.665 | $0.57 | SDA-2026-04-03-gap-s |
| #285 | Complement C1q Subtype Switching | C1QA | 0.665 | $0.57 | sda-2026-04-01-gap-0 |
| #286 | TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SASP and Synaptic Pruning | TNF, IL1B → GJA1 → C1Q/C3 | 0.663 | $0.55 | SDA-2026-04-12-gap-d |
| #287 | RNA Granule Nucleation Site Modulation | G3BP1 | 0.662 | $0.58 | sda-2026-04-01-gap-0 |
| #288 | Peripheral-Central Immune Decoupling Therapy | TREM2, complement cascade components | 0.662 | $0.59 | SDA-2026-04-04-gap-n |
| #289 | Circadian-Metabolic Microglial Reprogramming | CLOCK, BMAL1, PER2 | 0.662 | $0.57 | SDA-2026-04-04-gap-n |
| #290 | Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I Interferon Signaling | cGAS (CGAS) / STING (TMEM173) / IFNAR1/2 | 0.661 | $0.58 | SDA-2026-04-07-gap-p |
| #291 | Vascular mural cell degeneration precedes and exacerbates parenchymal pathology | PDGFRB | 0.661 | $0.56 | SDA-2026-04-04-analy |
| #292 | Biorhythmic Interference via Controlled Sleep Oscillations | GABRA1 | 0.661 | $0.56 | sda-2026-04-01-gap-0 |
| #293 | BBB Integrity Loss Defines Absolute Therapeutic Window Closure | MMP-9, Claudin-5, PDGFRβ (pericyte coverage) | 0.660 | $0.57 | SDA-2026-04-06-gap-d |
| #294 | SASP Modulation Rather Than Cell Elimination | NFKB1,IL1B,BDNF | 0.660 | $0.60 | SDA-2026-04-04-gap-s |
| #295 | Complement C1QA Inhibition Synergizes with PV Interneuron Modulation | C1QA, PVALB | 0.659 | $0.54 | SDA-2026-04-13-gap-p |
| #296 | Astrocyte IL-1β as Paracrine Mediator of Microglial Complement Expression | IL1B; IL1R1; MYD88 | 0.658 | $0.58 | SDA-2026-04-08-gap-p |
| #297 | TREM2 Activation as an Amplification Node for R136S Protection | TREM2 | 0.657 | $0.56 | SDA-2026-04-13-gap-p |
| #298 | Temporal TET2-Mediated Hydroxymethylation Cycling | TET2 | 0.657 | $0.55 | SDA-2026-04-04-gap-e |
| #299 | Mitochondrial RNA Granule Rescue Pathway | SYNCRIP | 0.656 | $0.55 | sda-2026-04-01-gap-v |
| #300 | Time-Dependent BBB Repair Strategy | MULTIPLE | 0.656 | $0.59 | SDA-2026-04-16-gap-b |
| #301 | Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins | CX3CR1 | 0.655 | $0.56 | sda-2026-04-01-gap-v |
| #302 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.655 | $0.60 | test-hypothesis-fixt |
| #303 | Astrocyte-Microglia Communication Rebalancing via Cytokine Modulation | IL1A, TNF, C1Q | 0.655 | $0.57 | SDA-2026-04-03-gap-d |
| #304 | Arginine Methylation Enhancement Therapy | PRMT1 | 0.653 | $0.60 | sda-2026-04-01-gap-0 |
| #305 | Microbial Inflammasome Priming Prevention | NLRP3, CASP1, IL1B, PYCARD | 0.653 | $0.66 | SDA-2026-04-01-gap-2 |
| #306 | KDM6A-Mediated H3K27me3 Rejuvenation | KDM6A | 0.653 | $0.57 | sda-2026-04-01-gap-v |
| #307 | Nucleolar Stress Response Normalization | NPM1 | 0.653 | $0.56 | sda-2026-04-01-gap-v |
| #308 | The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction | TFEB | 0.652 | $0.54 | SDA-2026-04-02-gap-v |
| #309 | SUMO1-Mediated Synaptotagmin-1 SUMOylation at Lys124 Impairs Calcium Sensing and Links Synaptic Dysfunction to SASP-Complement Activation | SUMO1, SYT1, C1QA, C3 | 0.652 | $0.58 | SDA-2026-04-16-gap-d |
| #310 | Microbiota-Microglia Axis Modulation | Multiple | 0.651 | $0.54 | SDA-2026-04-04-gap-2 |
| #311 | Astrocyte APOE4-Specific Lipid Metabolism Correction | APOE | 0.651 | $0.56 | SDA-2026-04-03-gap-s |
| #312 | C3aR Blockade Disrupts the Microglial-Astrocyte Feedforward Neurotoxic Loop | C3AR1, C3, NFKB1 | 0.651 | $0.60 | SDA-2026-04-14-gap-p |
| #313 | Mitochondrial Calcium Buffering Enhancement via MCU Modulation | MCU | 0.650 | $0.55 | sda-2026-04-01-gap-0 |
| #314 | NRF2-KEAP1 Pathway Activation to Coordinate Multi-Layer Antioxidant Defense | NRF2 (NFE2L2), KEAP1 | 0.650 | $0.56 | SDA-2026-04-16-gap-f |
| #315 | Loss of Homeostatic Epigenetic Identity Reprograms Microglia to Dystrophic State | EZH2/DNMT1/DNMT3A/P2RY12/TMEM119 | 0.650 | $0.57 | SDA-2026-04-06-gap-p |
| #316 | TNF-α/NF-κB Axis Upregulates P2RY12 in VSMCs | RELA (p65), IKBKB (IKKβ) | 0.650 | $0.57 | SDA-2026-04-07-gap-p |
| #317 | Pharmacologically Boost AQP4X Readthrough to Restore Perivascular Clearance | AQP4, AQP4X | 0.650 | $0.58 | SDA-2026-04-07-gap-p |
| #318 | NeuroD1-Mediated Astrocyte Reprogramming Attenuates Neuroinflammation Through Epigenetic Remodeling of A1 Astrocyte Signature Genes | NeuroD1/NF-kB | 0.650 | $0.58 | SDA-2026-04-04-gap-2 |
| #319 | APOE-Mediated Synaptic Lipid Raft Stabilization | SPTLC1 | 0.649 | $0.54 | sda-2026-04-01-gap-a |
| #320 | Glial Glycocalyx Remodeling Therapy | HSPG2 | 0.649 | $0.55 | sda-2026-04-01-gap-0 |
| #321 | CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk | CX3CR1 | 0.649 | $0.58 | SDA-2026-04-07-gap-d |
| #322 | Age-Dependent TREM2 Signaling Disrupts Astrocyte-Microglia Communication Leading to Senescent Glial Networks | TREM2 | 0.649 | $0.55 | SDA-2026-04-03-gap-a |
| #323 | TREM2-Mediated Oligodendrocyte-Microglia Metabolic Coupling in White Matter Neurodegeneration | TREM2 | 0.649 | $0.55 | SDA-2026-04-03-gap-a |
| #324 | APOE-TREM2 Ligand Availability Dysfunction in Neurodegeneration | APOE | 0.649 | $0.55 | SDA-2026-04-03-gap-a |
| #325 | Apoptosis-Senescence Decision Point Intervention | TP53,BAX,BAK1,CASP3 | 0.649 | $0.57 | SDA-2026-04-04-gap-s |
| #326 | IL-10-Producing B10 Cells Establish AQP4-Specific Peripheral Tolerance Through Macrophage Reprogramming | IL10, CSF1R, CD40 | 0.648 | $0.55 | SDA-2026-04-13-gap-p |
| #327 | CLU-APOE-TREM2 Tripartite Axis as a Coordinate Therapeutic Target | CLU-APOE-TREM2 axis (LXR/RXR pathway) | 0.648 | $0.57 | SDA-2026-04-14-gap-p |
| #328 | DNMT1-Targeting Antisense Oligonucleotide Reset | DNMT1 | 0.648 | $0.55 | sda-2026-04-01-gap-v |
| #329 | HCN1-Mediated Resonance Frequency Stabilization Therapy | HCN1 | 0.648 | $0.54 | sda-2026-04-01-gap-0 |
| #330 | Mitochondrial SPM Synthesis Platform Engineering | ALOX5 | 0.647 | $0.53 | sda-2026-04-01-gap-0 |
| #331 | Epigenetic Reprogramming of Microglial Memory | DNMT3A, HDAC1/2 | 0.647 | $0.57 | SDA-2026-04-04-gap-2 |
| #332 | Inflammatory State-Dependent Ketone Timing | IRAKM | 0.647 | $0.56 | SDA-2026-04-03-gap-d |
| #333 | Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement | IDH2 | 0.646 | $0.55 | sda-2026-04-01-gap-0 |
| #334 | Activity-Dependent Synaptic Tagging via CREB-BDNF-TrkB Signaling | CREB1, BDNF, NTRK2 (TrkB) | 0.646 | $0.58 | SDA-2026-04-07-gap-p |
| #335 | Synthetic Biology Rewiring via Orthogonal Receptors | CNO | 0.645 | $0.56 | sda-2026-04-01-gap-0 |
| #336 | Ephrin-B2/EphB4 Axis Manipulation | EPHB4 | 0.645 | $0.55 | sda-2026-04-01-gap-0 |
| #337 | Oligodendrocyte Remyelination Enhancement | TREM2 | 0.644 | $0.58 | SDA-2026-04-03-gap-a |
| #338 | Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy | - | 0.644 | $0.56 | SDA-2026-04-15-gap-p |
| #339 | Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis | MTOR/HIF1α | 0.644 | $0.58 | SDA-2026-04-07-gap-d |
| #340 | H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Pruning to Amyloid Clearance | TREM2 | 0.644 | $0.57 | SDA-2026-04-26-trem2 |
| #341 | White Matter Immune Checkpoint Restoration | CXCL10 | 0.644 | $0.56 | SDA-2026-04-03-gap-a |
| #342 | Cell-Type Specific Metabolic Reprogramming | PPARA | 0.643 | $0.54 | SDA-2026-04-03-gap-s |
| #343 | Epigenetic Silencing of AIF1 Gene Locus by Chronic Inflammation | DNMT1/DNMT3A | 0.643 | $0.58 | SDA-2026-04-07-gap-p |
| #344 | SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis | HK2/PFKFB3 | 0.643 | $0.65 | sda-2026-04-01-gap-0 |
| #345 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.642 | $0.76 | SDA-2026-04-03-gap-a |
| #346 | TREM2-Mediated Mitochondrial Dysfunction in Neurodegeneration | TREM2 | 0.642 | $0.54 | SDA-2026-04-03-gap-a |
| #347 | TREM2-Driven Senescence Biomarker Index for Predicting Neurodegeneration Risk | TREM2 | 0.642 | $0.55 | SDA-2026-04-03-gap-a |
| #348 | Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding | CSGA | 0.642 | $0.54 | SDA-2026-04-01-gap-2 |
| #349 | Glycine-Rich Domain Competitive Inhibition | TARDBP | 0.640 | $0.56 | sda-2026-04-01-gap-0 |
| #350 | Colonic Th17/IL-17A Axis → Peripheral Immune Recruitment to SN and Neuronal Apoptosis | RORC (RORγt), IL17A, IL17RA, IL17RC, CXCL9, CXCL10, CXCR3, CD8A | 0.640 | $0.57 | sda-2026-04-01-gap-2 |
| #351 | Heterogeneous astrocyte activation states differentially impact neuronal survival across AD progression | GFAP | 0.640 | $0.55 | SDA-2026-04-04-analy |
| #352 | Transglutaminase-2 Cross-Linking Inhibition Strategy | TGM2 | 0.639 | $0.56 | SDA-2026-04-01-gap-9 |
| #353 | Mitochondrial NAD+ Salvage Enhancement | STING1 | 0.639 | $0.55 | SDA-2026-04-03-gap-a |
| #354 | Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms | SOD1, HTT, TARDBP | 0.638 | $0.56 | SDA-2026-04-03-gap-c |
| #355 | Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in Early Amyloid Phase | TREM2 | 0.637 | $0.58 | SDA-2026-04-02-gap-0 |
| #356 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.637 | $0.60 | test-hypothesis-fixt |
| #357 | Astrocyte Metabolic Reprogramming via APOE4 Correction | APOE | 0.636 | $0.58 | SDA-2026-04-03-gap-s |
| #358 | TREM2-Dependent Microglial Phagocytosis Acts as a Strain Selection Filter | TREM2 | 0.636 | $0.58 | SDA-2026-04-15-gap-d |
| #359 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.634 | $0.61 | SDA-2026-04-04-gap-t |
| #360 | Liver-Derived Inflammatory Suppressors Downregulate Microglial IBA1 | STAT3/JAK1 | 0.633 | $0.57 | SDA-2026-04-07-gap-p |
| #361 | Palmitoylethanolamide-Based Endocannabinoid Therapy | PPARA | 0.633 | $0.54 | SDA-2026-04-16-gap-b |
| #362 | TREM2 R47H Variant Correction — AAV-Mediated Rescue of Common Risk Allele | TREM2 | 0.631 | $0.57 | SDA-2026-04-02-gap-0 |
| #363 | Disease-Associated Microglia Metabolic Reprogramming | TREM2 | 0.631 | $0.57 | SDA-2026-04-03-gap-s |
| #364 | C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages | C1QA/C1QC | 0.631 | $0.56 | SDA-2026-04-07-gap-p |
| #365 | FOXO3-Longevity Pathway Epigenetic Reprogramming | FOXO3 | 0.630 | $0.55 | sda-2026-04-01-gap-v |
| #366 | Epigenetic Bivalency at CDKN2A Locus Distinguishes Senescent from Activated Microglia | CDKN2A, H3K9me3, DREAM complex (LIN9, LIN37, RBL2) | 0.630 | $0.57 | SDA-2026-04-06-gap-d |
| #367 | Intestinal Permeability Defects → Systemic LPS Translocation → Microglial Priming | Tight junction complex (CLDN1, OCLN, TJP1), LBP, CD14, TLR4, MYD88, NFKB1 | 0.630 | $0.57 | sda-2026-04-01-gap-2 |
| #368 | Programmable Neuronal Circuit Repair via Epigenetic CRISPR | NURR1, PITX3, neuronal identity transcription factors | 0.630 | $0.52 | SDA-2026-04-03-gap-c |
| #369 | CX3CR1 Agonism Enhances Microglial Phagocytosis of Extracellular Tau Seeds, Preventing Template-Dependent Misfolding | CX3CR1 | 0.630 | $0.57 | SDA-2026-04-04-gap-2 |
| #370 | Combine Anti-AQP4 Autoimmunity Control with Astrocyte-Endfoot Repair in NMOSD | AQP4, IL6R, CD19, C5 | 0.630 | $0.57 | SDA-2026-04-07-gap-p |
| #371 | Selective Cholinergic Protection via APP Pathway Modulation | APP | 0.629 | $0.58 | SDA-BIOMNI-CLINICAL- |
| #372 | Gut-Brain Axis M-Cell Modulation | GP2, SPIB | 0.629 | $0.56 | SDA-2026-04-04-gap-n |
| #373 | APOE4-Driven Astrocyte Senescence as Primary Target | APOE,CDKN1A,BCL2L1 | 0.629 | $0.56 | SDA-2026-04-04-gap-s |
| #374 | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | Disease-causing mutations with integrated reporters | 0.629 | $0.52 | SDA-2026-04-03-gap-c |
| #375 | TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplification | TREM2 | 0.628 | $0.59 | SDA-2026-04-02-gap-0 |
| #376 | Quantum Coherence Disruption in Cellular Communication | TUBB3 | 0.627 | $0.54 | sda-2026-04-01-gap-0 |
| #377 | Cardiovascular-Neuroinflammatory Dual Targeting | TNF/IL6 | 0.627 | $0.55 | SDA-2026-04-04-gap-2 |
| #378 | TREM2 Super-Agonist Induction of DAM Program | TREM2 | 0.627 | $0.54 | SDA-2026-04-16-gap-2 |
| #379 | Default Mode Network Circuit Stabilization | VIP | 0.627 | $0.54 | SDA-2026-04-03-26abc |
| #380 | Peripheral-to-Central Inflammation Circuit Breaker | IL1B | 0.626 | $0.57 | SDA-2026-04-16-gap-b |
| #381 | Microglial TREM2 downregulation impairs damage-associated response in late-stage Alzheimer's disease | TREM2 | 0.626 | $0.57 | SDA-2026-04-04-analy |
| #382 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.625 | $0.76 | SDA-2026-04-03-gap-a |
| #383 | Heat Shock Protein 70 Disaggregase Amplification | HSPA1A | 0.625 | $0.56 | sda-2026-04-01-gap-0 |
| #384 | Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics | ANXA1 | 0.625 | $0.54 | sda-2026-04-01-gap-v |
| #385 | Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysosomal membrane permeabilization | LGALS3 | 0.625 | $0.56 | SDA-2026-04-04-gap-l |
| #386 | Autophagy-Senescence Axis Therapeutic Window | ATG7,BCL2,BCL2L1 | 0.624 | $0.58 | SDA-2026-04-04-gap-s |
| #387 | Serine/Arginine-Rich Protein Kinase Modulation | SRPK1 | 0.624 | $0.53 | sda-2026-04-01-gap-0 |
| #388 | Myelin Sulfatide Restoration | GAL3ST1 | 0.623 | $0.56 | SDA-2026-04-03-gap-a |
| #389 | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | TFEB | 0.622 | $0.53 | SDA-2026-04-03-gap-a |
| #390 | Cholesterol-CRISPR Convergence Therapy for Neurodegeneration | HMGCR, LDLR, APOE regulatory regions | 0.622 | $0.54 | SDA-2026-04-03-gap-c |
| #391 | Pharmacological Enhancement of APOE4 Glycosylation | ST6GAL1, FUT8 | 0.622 | $0.52 | sda-2026-04-01-gap-0 |
| #392 | Microglial ACE Enhancement for Amyloid Clearance | ACE | 0.622 | $0.55 | SDA-2026-04-03-gap-a |
| #393 | Vagal Afferent Microbial Signal Modulation | GLP1R, BDNF | 0.621 | $0.55 | SDA-2026-04-01-gap-2 |
| #394 | Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery | TRAK1_KIF5A | 0.621 | $0.54 | sda-2026-04-01-gap-v |
| #395 | Sphingolipid Metabolism Reprogramming | CERS2 | 0.620 | $0.54 | sda-2026-04-01-gap-0 |
| #396 | Metabolic Rewiring via SPP1-Induced HIF1α Glycolytic Shift | HIF1A (HIF1α), MTOR (mTORC1), EGLN1 (PHD2) | 0.620 | $0.57 | SDA-2026-04-06-gap-p |
| #397 | Cross-Cell Type Synaptic Rescue via Tripartite Synapse Restoration | SYN1, SLC1A2, and CX3CR1 | 0.620 | $0.56 | SDA-2026-04-03-gap-s |
| #398 | TREM2 Agonism to Reprogram Infiltrated Monocytes Toward Neuroprotective Phenotype | TREM2 | 0.620 | $0.56 | SDA-2026-04-13-gap-d |
| #399 | Tau fibrils expose neuronal phosphatidylserine and heat-shock protein 70, driving microglial non-complement synaptic engulfment in primary tauopathies | Phosphatidylserine, TIMD4, HSPA1A/HSPA1B, SCARF1, LRP8 | 0.620 | $0.57 | SDA-2026-04-02-gap-s |
| #400 | Microglial xCT/SLC7A11 Selective Inhibition to Reduce Non-Cell-Autonomous Glutamate Toxicity | SLC7A11 | 0.620 | $0.55 | SDA-2026-04-16-gap-f |
| #401 | Selective cathepsin B inhibition prevents cathepsin leakage-mediated NLRP3 inflammasome activation without impairing normal proteolysis | CTSB | 0.620 | $0.57 | SDA-2026-04-04-gap-l |
| #402 | C1Q-Induced Foam Cell Formation via Scavenger Receptor Upregulation | C1QA/C1QC | 0.620 | $0.56 | SDA-2026-04-07-gap-p |
| #403 | CX3CR1-Targeted HDAC3 Knockdown in Microglia via AAV9 Delivery | HDAC3 (class I histone deacetylase) | 0.620 | $0.56 | SDA-2026-04-08-gap-d |
| #404 | Lysosomal pH Restoration Upstream of TFEB | ATP6V1A | 0.619 | $0.56 | SDA-2026-04-03-gap-d |
| #405 | TREM2-Dependent Microglial Senescence Transition | TREM2 | 0.618 | $0.55 | SDA-BIOMNI-SCRNA_AN- |
| #406 | Complement Cascade Specificity: Microglial C3aR Antagonism Downstream of SPP1 | C3/C3aR | 0.618 | $0.56 | SDA-2026-04-07-gap-p |
| #407 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.618 | $0.67 | SDA-2026-04-04-gap-t |
| #408 | Low Complexity Domain Cross-Linking Inhibition | TGM2 | 0.617 | $0.54 | sda-2026-04-01-gap-0 |
| #409 | LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasome Activation and SPP1 Induction | SPP1 | 0.617 | $0.56 | SDA-2026-04-06-gap-p |
| #410 | Perinatal Immune Challenge Prevention | Multiple | 0.616 | $0.53 | SDA-2026-04-04-gap-2 |
| #411 | Spatially-Targeted Regional Vulnerability Prevention | Regional vulnerability genes | 0.616 | $0.54 | SDA-2026-04-03-gap-s |
| #412 | Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic Windows | TFEB, MAPK14, MAPKAPK2, IL6, CXCL1 | 0.614 | $0.56 | SDA-2026-04-07-gap-d |
| #413 | Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade | AGER | 0.613 | $0.52 | SDA-2026-04-01-gap-2 |
| #414 | Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting | HTT, DMPK, repeat-containing transcripts | 0.613 | $0.55 | SDA-2026-04-03-gap-c |
| #415 | Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering | TDC | 0.612 | $0.53 | SDA-2026-04-01-gap-2 |
| #416 | SIRT6-NAD+ Axis Enhancement Therapy | SIRT6 | 0.612 | $0.54 | sda-2026-04-01-gap-v |
| #417 | Complement-Mediated Synaptic Pruning Dysregulation | C1QA | 0.612 | $0.53 | SDA-2026-04-03-gap-a |
| #418 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.612 | $0.58 | test-hypothesis-fixt |
| #419 | Synaptic Pruning Precision Therapy | C1QA, C3, CX3CR1, CX3CL1 | 0.612 | $0.57 | SDA-2026-04-04-gap-2 |
| #420 | HDAC3-Dependent A1 Astrocyte Commitment Window | HDAC3 | 0.611 | $0.56 | SDA-2026-04-07-gap-d |
| #421 | Epigenetic Memory Reprogramming for Alzheimer's Disease | BDNF, CREB1, synaptic plasticity genes | 0.611 | $0.55 | SDA-2026-04-03-gap-c |
| #422 | APOE4-Lipid Metabolism Correction | APOE | 0.610 | $0.56 | SDA-2026-04-04-gap-2 |
| #423 | Astrocyte LRP1-mediated tau uptake and APOE4-dependent secretion creates regional susceptibility gradients | LRP1 | 0.610 | $0.56 | SDA-2026-04-07-gap-d |
| #424 | Age-Accelerated miR-155 Upregulation Primes Nigral Microglia for Parkinson's Disease Pathology | miR-155 | 0.610 | $0.56 | SDA-2026-04-06-gap-p |
| #425 | H1: Senolytic Clearance of Senescent APOE4 Astrocytes | CDKN2A (p16Ink4a) | 0.610 | $0.56 | SDA-2026-04-06-gap-d |
| #426 | Female microglia exhibit heightened complement gene expression and pruning capacity via estrogen-regulated epigenetic sensitization, explaining the female AD risk advantage | ESR2 (NR3A2), KDM6A (UTX), C1QA, C1QB, NFKB1 | 0.610 | $0.56 | SDA-2026-04-02-gap-s |
| #427 | APOE4 preferentially signals through LRP1 over LDLR, altering endosomal cholesterol trafficking and causing lysosomal cholesterol sequestration that drives lysosomal dysfunction and inflammation | LRP1, NPC1, CTSD | 0.610 | $0.56 | SDA-2026-04-04-gap-a |
| #428 | H2: Perforant Path Synapse Loss via Early Complement Cascade Activation | C1QA, C1QB, C3, ITGAM | 0.610 | $0.56 | SDA-2026-04-02-gap-e |
| #429 | Aberrant Galectin-3 Expression on Stressed Synapses Creates Bridging Molecules | LGALS3 (Galectin-3) | 0.610 | $0.57 | SDA-2026-04-07-gap-p |
| #430 | Microglial priming is primarily epigenetic, with metabolic changes acting as coupled consequences or cofactors | KDM6B | 0.609 | $0.55 | SDA-2026-04-07-gap-d |
| #431 | Temporal TFEB Modulation Therapy | TFEB | 0.609 | $0.54 | SDA-2026-04-03-gap-d |
| #432 | The Glial Ketone Metabolic Shunt Hypothesis | HMGCS2 | 0.608 | $0.55 | SDA-2026-04-02-gap-v |
| #433 | Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function | DDC | 0.606 | $0.52 | SDA-2026-04-01-gap-2 |
| #434 | Circadian-Gated Ketone Window Hypothesis | OXCT1 | 0.606 | $0.57 | SDA-2026-04-03-gap-d |
| #435 | TREM2-Mediated Microglial Checkpoint Therapy | TREM2 | 0.606 | $0.54 | SDA-2026-04-03-gap-s |
| #436 | HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM Transition | HK2 | 0.605 | $0.61 | SDA-2026-04-16-gap-d |
| #437 | TREM2-Microglial Clearance Enhancement as Common Mechanism for Injury Prevention | TREM2 | 0.604 | $0.58 | SDA-2026-04-14-gap-p |
| #438 | Selective TFEB Cofactor Enhancement | TFE3 | 0.602 | $0.54 | SDA-2026-04-03-gap-d |
| #439 | NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/SIRT1 Activator for Reverse Senescence | SIRT1 | 0.602 | $0.56 | SDA-2026-04-26-gap-p |
| #440 | STING Antagonism Prevents Acute-to-Chronic Neuroinflammation Transition via Interruption of IFN-I Feedback Looping | TMEM173 (STING) | 0.601 | $0.58 | SDA-2026-04-15-gap-p |
| #441 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.600 | $0.72 | SDA-2026-04-04-gap-t |
| #442 | TREM2-Dependent Senescent Microglia Disrupt Astrocyte Communication Networks | TREM2/TYROBP | 0.600 | $0.55 | SDA-2026-04-03-gap-a |
| #443 | TREM2-Mediated Oligodendrocyte-Microglia Cross-talk in White Matter Neurodegeneration | TREM2 | 0.600 | $0.58 | SDA-2026-04-03-gap-a |
| #444 | TNF-α–C1r/C1s Bridge Between NF-κB and Classical Complement Cascade | TNF; TNFRSF1A; C1R; C1S | 0.600 | $0.55 | SDA-2026-04-08-gap-p |
| #445 | mTORC1 Hyperactivation Impairs Autophagic Flux and Drives Senescence | MTOR/TFEB/TFE3 | 0.600 | $0.55 | SDA-2026-04-06-gap-p |
| #446 | C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion | C1QA/C1QC | 0.600 | $0.55 | SDA-2026-04-07-gap-p |
| #447 | TREM2-Mediated Astroglial Reactivity in Neurodegeneration | TREM2 | 0.600 | $0.57 | SDA-2026-04-03-gap-a |
| #448 | APOE4 Induces Region-Specific Microglial Senescence Driving Frontal Cortex Neurodegeneration | APOE4 | 0.600 | $0.56 | SDA-2026-04-06-gap-p |
| #449 | Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therapy | CST, GAL3ST1 | 0.599 | $0.54 | SDA-2026-04-03-gap-d |
| #450 | OPC differentiation blockade contributes to white matter degeneration in early-stage AD | PDGFRA | 0.599 | $0.55 | SDA-2026-04-04-analy |
| #451 | Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits | PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes | 0.599 | $0.52 | SDA-2026-04-03-gap-c |
| #452 | Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Metabolites Promotes A2 Polarization | AHR, CYP1A1, NFKB1, IL6 | 0.597 | $0.57 | SDA-2026-04-14-gap-p |
| #453 | Glycosaminoglycan Template Disruption Approach | HSPG2 | 0.597 | $0.53 | SDA-2026-04-01-gap-9 |
| #454 | Selective C1q-CRP vs. C1q-IgG Axis Inhibition | C1QA/C1QB/C1QC, CRP, FCGR1A | 0.597 | $0.57 | SDA-2026-04-16-gap-p |
| #455 | Brain Insulin Resistance with Glucose Transporter Dysfunction | GLUT3/GLUT4 | 0.596 | $0.55 | SDA-2026-04-02-gap-v |
| #456 | Netrin-1 Gradient Restoration | NTN1 | 0.595 | $0.54 | sda-2026-04-01-gap-0 |
| #457 | VCP-Mediated Autophagy Enhancement | VCP | 0.595 | $0.64 | SDA-2026-04-04-gap-t |
| #458 | NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification | NAMPT, SIRT1 | 0.592 | $0.57 | SDA-2026-04-16-gap-2 |
| #459 | TREM2-C1Q Competitive Binding to Prevent Complement-Mediated Cholinergic Synapse Loss | TREM2,C1Q | 0.591 | $0.56 | SDA-2026-04-16-gap-p |
| #460 | Neuronal MHC Class I Expression as a Selectivity Determinant | H2-Kb (H2-K1), Lilrb4 (LilrB2) | 0.591 | $0.56 | SDA-2026-04-07-gap-p |
| #461 | Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation | SOD1, TARDBP, BDNF, GDNF, IGF-1 | 0.590 | $0.54 | SDA-2026-04-03-gap-c |
| #462 | Microglial Replacement and Ontogeny Shift | CCR2 | 0.590 | $0.56 | SDA-2026-04-07-gap-d |
| #463 | TREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocyte Tau Clearance Networks | TREM2 | 0.589 | $0.56 | SDA-2026-04-03-26abc |
| #464 | Cardiovascular-Neuroinflammation Crosstalk Interruption | IL1B, TNFA, NLRP3 | 0.587 | $0.56 | SDA-2026-04-04-gap-2 |
| #465 | TREM2-Mediated Oligodendrocyte-Microglia Signaling in White Matter Neurodegeneration | TREM2 | 0.587 | $0.56 | SDA-2026-04-03-gap-a |
| #466 | TNFRSF25-Mediated Aging Exosome Pathway Inhibition | TNFRSF25 | 0.587 | $0.54 | SDA-2026-04-03-gap-a |
| #467 | TREM2 Signaling Bifurcation with Independent TYROBP-Independent Homeostatic Maintenance | TREM2 | 0.586 | $0.56 | SDA-2026-04-14-gap-p |
| #468 | Senescence-Tau Decoupling Therapy | CDKN2A | 0.585 | $0.54 | SDA-2026-04-03-gap-a |
| #469 | Mitochondrial-Lysosomal Coupling Enhancer | LAMTOR1 | 0.585 | $0.54 | SDA-2026-04-03-gap-d |
| #470 | P2RY12-driven autophagy impairment in cerebral VSMCs mediates BBB breakdown and neurovascular unit dysfunction | P2RY12 | 0.585 | $0.55 | SDA-2026-04-07-gap-p |
| #471 | FcRn Transport Bypass Strategy | LDLR | 0.585 | $0.52 | SDA-2026-04-12-gap-d |
| #472 | APOE4 Creates Accelerated, Compressed Reversibility Window | APOE/TREM2 axis, APOE-TREM2 physical interaction | 0.584 | $0.54 | SDA-2026-04-06-gap-d |
| #473 | TREM2-Mediated Selective Aggregate Clearance Pathway | TREM2 | 0.584 | $0.52 | SDA-2026-04-01-gap-9 |
| #474 | IGFBPL1-Mediated Homeostatic Restoration | IGFBPL1 | 0.584 | $0.56 | SDA-2026-04-04-gap-2 |
| #475 | Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion Amplifies SST Interneuron-Targeted Neuromodulation | - | 0.583 | $0.54 | SDA-2026-04-26-gap-p |
| #476 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.582 | $0.58 | SDA-2026-04-04-gap-t |
| #477 | ITGAM/CD11b direct binding explains microglial phagocytosis blockade | ITGAM | 0.582 | $0.55 | SDA-2026-04-21-gap-d |
| #478 | CSF1R Inhibition-Mediated Microglial Replacement as a State Transition Reset | CSF1R | 0.581 | $0.57 | SDA-2026-04-16-gap-d |
| #479 | Neuroinflammation-Driven TDP-43 Mislocalization via Microglial APOE4 Signaling | NLRP3, LRP1, IL1B, TNF | 0.580 | $0.54 | SDA-2026-04-07-gap-p |
| #480 | H7: Dual-Target Strategy (Senolytics + APOE4→3 Conversion) | APOE; CDKN2A | 0.580 | $0.55 | SDA-2026-04-06-gap-d |
| #481 | H5: Complement Dysregulation Drives Synapse Loss via Senescent APOE4 Astrocytes | C3; C3AR1; C5AR1 | 0.580 | $0.55 | SDA-2026-04-06-gap-d |
| #482 | Microglial Priming via NF-κB-Dependent DAM Phenotype and Complement Biosynthesis | NFKB1; IKBKB; C1QA; C3 | 0.580 | $0.55 | SDA-2026-04-08-gap-p |
| #483 | αvβ3 Integrin-FAK-SYK-CARD9/NF-κB Pathway | ITGAV/ITGB3 (αvβ3 heterodimer), PTK2 (FAK), SYK, CARD9 | 0.580 | $0.55 | SDA-2026-04-06-gap-p |
| #484 | Astrocyte cGAS/STING Activation Converts Protective into Destructive Neuroinflammation | STING (TMEM173) in astrocytes (GFAP+ cells) | 0.580 | $0.55 | SDA-2026-04-07-gap-p |
| #485 | TREM2-Driven Phagocytic Receptor Cascades Determine Mitochondrial Antigen Presentation vs. Intracellular Mitophagy | TREM2 | 0.580 | $0.55 | SDA-2026-04-08-gap-p |
| #486 | AQP4 Missorting in Reactive Astrocytes Drives Glymphatic Failure in Chronic Neurodegeneration | AQP4; STAT3; MMP9 | 0.580 | $0.55 | SDA-2026-04-07-gap-p |
| #487 | Female Microglia Exhibit Reduced P2Y12 Expression Conferring Neuroprotection Through Attenuated Chemotaxis | P2RY12 | 0.580 | $0.55 | SDA-2026-04-06-gap-p |
| #488 | APOE4 drives astrocyte metabolic reprogramming toward glycolysis via PGC-1α suppression, reducing fatty acid oxidation and promoting lipogenesis that feeds pathological lipid droplet formation | PPARGC1A (PGC-1α), SIRT1, SREBF1 (SREBP1c) | 0.580 | $0.55 | SDA-2026-04-04-gap-a |
| #489 | LAMP-2 replacement therapy prevents lysosomal membrane permeabilization and downstream NLRP3 activation | LAMP2 (LGMN) | 0.580 | $0.55 | SDA-2026-04-04-gap-l |
| #490 | Complement-Mediated Synaptic Protection | C1QA | 0.580 | $0.54 | SDA-2026-04-04-gap-2 |
| #491 | IGFBPL1-Mediated Microglial Reprogramming | IGFBPL1 | 0.579 | $0.54 | SDA-2026-04-04-gap-2 |
| #492 | TREM2-Astrocyte Communication in Microglial Dysfunction | TREM2 | 0.579 | $0.56 | SDA-2026-04-03-gap-a |
| #493 | Spatial Transcriptome-Guided Precision Cell Therapy | SOX10 and DLX1/2 | 0.578 | $0.54 | SDA-2026-04-03-gap-s |
| #494 | Synaptic Vesicle Tau Capture Inhibition | SNAP25 | 0.578 | $0.59 | SDA-2026-04-04-gap-t |
| #495 | Dynamic Microglial Phenotype Switching Biomarker Panel for Neuroinflammatory Treatment Stratification | TREM2 | 0.577 | $0.56 | SDA-2026-04-16-gap-p |
| #496 | TREM2 Promoter Silencing via DNA Hypermethylation | TREM2 | 0.576 | $0.55 | SDA-2026-04-07-gap-d |
| #497 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.575 | $0.74 | SDA-2026-04-04-gap-t |
| #498 | TREM2-Senescence Cascade in Astrocyte-Microglia Communication Breakdown | TREM2 | 0.574 | $0.56 | SDA-2026-04-03-gap-a |
| #499 | Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment to restore hippocampal-cortical connectivity in early MCI | PVALB | 0.573 | $0.55 | SDA-2026-04-03-26abc |
| #500 | TREM2-P2RY12 Balance Restoration Therapy | TREM2 | 0.571 | $0.55 | SDA-2026-04-04-gap-2 |
| #501 | Disease-Associated Microglia (DAM) Program Drives IBA1 Downregulation | TREM2/TYROBP | 0.571 | $0.54 | SDA-2026-04-07-gap-p |
| #502 | PINK1/PARK2-Mediated Mitophagy Enhancement for Neuroinflammation Control | PINK1 | 0.571 | $0.55 | SDA-2026-04-03-gap-i |
| #503 | Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization | SNCA | 0.571 | $0.55 | SDA-BIOMNI-BINDER_D- |
| #504 | Direct NF-κB Transcriptional Regulation of C1q Genes in Microglia | RELA; C1QA/C1QB/C1QC | 0.570 | $0.55 | SDA-2026-04-08-gap-p |
| #505 | CX3CR1-Negative Trem2-High Microglial Subset Mediates Female Resilience via Estrogen Receptor-alpha Suppression of NLRP3 | ESR1 | 0.570 | $0.55 | SDA-2026-04-06-gap-p |
| #506 | Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibition | HDAC6 (class IIb histone deacetylase) | 0.570 | $0.55 | SDA-2026-04-08-gap-d |
| #507 | Blocking Astrocyte-Mediated Tau Re-Spreading via Cx43 Hemichannel Inhibition | GJA1 (Connexin-43) | 0.570 | $0.54 | SDA-2026-04-04-gap-t |
| #508 | TREM2-Dependent Microglial Surveillance Controls AQP4-Mediated Tau Clearance Through Astrocytic Endfoot Maintenance | TREM2 | 0.569 | $0.56 | SDA-2026-04-03-26abc |
| #509 | Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated Amplification | MAPT | 0.568 | $0.55 | SDA-2026-04-03-26abc |
| #510 | Tau-Independent Microtubule Stabilization via MAP6 Enhancement | MAP6 | 0.567 | $0.56 | sda-2026-04-01-gap-0 |
| #511 | NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplification | NLRP3 | 0.566 | $0.54 | SDA-2026-04-12-gap-d |
| #512 | Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation | GJA1 | 0.566 | $0.58 | sda-2026-04-01-gap-v |
| #513 | CX43 hemichannel engineering enables size-selective mitochondrial transfer | GJA1 | 0.566 | $0.55 | sda-2026-04-01-gap-v |
| #514 | HIF1A stabilization lowers the activation threshold of circadian-disrupted microglia | HIF1A | 0.566 | $0.55 | SDA-2026-04-07-gap-d |
| #515 | Vascular-Glial Interface Restoration | CLDN5 | 0.566 | $0.54 | SDA-2026-04-03-gap-s |
| #516 | NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation | NLRP3 | 0.566 | $0.55 | SDA-2026-04-07-gap-d |
| #517 | Temporal Gating of Microglial Responses | CLOCK, ARNTL | 0.565 | $0.54 | SDA-2026-04-04-gap-2 |
| #518 | GluN2B-Mediated Microglial Activation and Tau Propagation | GRIN2B | 0.565 | $0.51 | SDA-2026-04-03-26abc |
| #519 | Ketone-Primed Thalamocortical Enhancement of Glymphatic Tau Clearance | GRIN2B | 0.565 | $0.51 | SDA-2026-04-03-26abc |
| #520 | Closed-loop tACS targeting EC-II somatostatin interneurons to restore dendritic integration and prevent tau-mediated HCN channel dysfunction in AD | SST | 0.564 | $0.53 | SDA-2026-04-03-26abc |
| #521 | Closed-loop transcranial focused ultrasound targeting entorhinal PV interneurons to restore AnkyrinG-dependent AIS integrity and hippocampal gamma synchrony in Alzheimer's disease | PVALB | 0.564 | $0.53 | SDA-2026-04-03-26abc |
| #522 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymphatic-mediated amyloid clearance and secondary PV interneuron disinhibition in Alzheimer's disease | AQP4 | 0.564 | $0.53 | SDA-2026-04-03-26abc |
| #523 | Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senescent Microglia to Prevent SASP-Driven Complement Cascade Amplification | CDKN2A (p16^Ink4a), CDKN1A (p21^Cip1/Waf1) | 0.564 | $0.56 | SDA-2026-04-15-gap-p |
| #524 | P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming | P2RX7/NLRP3 | 0.563 | $0.54 | SDA-2026-04-06-gap-d |
| #525 | Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators | CX3CR1 | 0.563 | $0.53 | sda-2026-04-01-gap-v |
| #526 | Complement C1q Suppression as Mechanism Linking Exercise Plasma to PV Interneuron Protection | C1QA | 0.560 | $0.56 | SDA-2026-04-14-gap-p |
| #527 | MOG-IgG induces spinal cord demyelination through Fcγ receptor-dependent macrophage activation | MOG, FCGR1A, FCGR3A, FCGR2A, SYK, IRAK4 | 0.560 | $0.54 | SDA-2026-04-08-gap-p |
| #528 | AQP4 Autoantibodies in NMOSD Cause Bystander Oligodendrocyte Injury via Metabolic Coupling Disruption | AQP4; SLC16A1 (MCT1); SLC16A3 (MCT4) | 0.560 | $0.54 | SDA-2026-04-07-gap-p |
| #529 | Persistent γH2AX+53BP1 Foci with DREAM Complex Activation Defines Irreversibly Arrested Microglia | H2AFX (γH2AX), TP53BP1, DREAM complex (LIN9, LIN37, RBL2, E2F4) | 0.560 | $0.54 | SDA-2026-04-06-gap-d |
| #530 | Temporal cGAS-STING Activation Stage-Specific Therapeutic Targeting | STING (TMEM173) | 0.560 | $0.54 | SDA-2026-04-07-gap-p |
| #531 | Circadian-Gated Maresin Biosynthesis Amplification | ALOX12 | 0.557 | $0.56 | sda-2026-04-01-gap-0 |
| #532 | Gut-Brain Axis Microbiome Modulation | GPR43, GPR109A | 0.557 | $0.54 | SDA-2026-04-04-gap-2 |
| #533 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.555 | $0.55 | test-hypothesis-fixt |
| #534 | CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal | CYP46A1 | 0.555 | $0.56 | SDA-2026-04-26-trem2 |
| #535 | Inhibitory Neuron-Selective WNT Signaling Restoration | WNT3A, CTNNB1, TCF7L2 | 0.554 | $0.53 | SDA-2026-04-03-gap-d |
| #536 | Profilin-1 Cytoskeletal Checkpoint Enhancement | PFN1 | 0.554 | $0.53 | SDA-2026-04-03-gap-a |
| #537 | Dual NF-κB/MMP Inhibition Strategy | NFKB1 | 0.554 | $0.55 | SDA-2026-04-16-gap-b |
| #538 | P2RX7-Mediated Exosome Secretion Blockade | P2RX7 | 0.552 | $0.57 | SDA-2026-04-04-gap-t |
| #539 | Liquid-Liquid Phase Separation Modifier Therapy | G3BP1 | 0.551 | $0.53 | SDA-2026-04-01-gap-9 |
| #540 | Astrocytic SPP1 Modulation Through STAT3-Dependent Transcriptional Control | SPP1 | 0.551 | $0.56 | SDA-2026-04-15-gap-p |
| #541 | Temporal NLRP3 Inhibition During SPP1-Driven Microglial Activation Windows | NLRP3 | 0.551 | $0.56 | SDA-2026-04-15-gap-p |
| #542 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via astrocytic calcium signaling and potassium buffering in Alzheimer's disease | AQP4 | 0.551 | $0.55 | SDA-2026-04-03-26abc |
| #543 | Oligodendrocyte DNA Repair Enhancement | PARP1 | 0.550 | $0.52 | SDA-2026-04-03-gap-s |
| #544 | Digital Twin-Guided Metabolic Reprogramming | PPARGC1A/PRKAA1 | 0.550 | $0.54 | sda-2026-04-01-gap-0 |
| #545 | H2: SASP Neutralization via JAK/STAT Inhibition Preserves Astrocyte Function | IL6R; JAK1; STAT3 | 0.550 | $0.54 | SDA-2026-04-06-gap-d |
| #546 | Surface Exposure of SENP1-β1 Integrin Complex Enables Targeted Senolytic Elimination | SENP1, ITGB1 (β1 integrin), ITGAM (CD11b) | 0.550 | $0.53 | SDA-2026-04-06-gap-d |
| #547 | Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade | NAMPT, SIRT1, C1QA/C1QB/C1QC, IL1B | 0.549 | $0.55 | SDA-2026-04-16-gap-p |
| #548 | Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy | RHOT1 | 0.549 | $0.51 | SDA-2026-04-01-gap-2 |
| #549 | YWHAG-Mediated TFEB Subcellular Targeting | YWHAG | 0.549 | $0.53 | SDA-2026-04-03-gap-d |
| #550 | Perinatal Hypoxia-Primed Microglia Targeting | HIF1A, NFKB1 | 0.548 | $0.53 | SDA-2026-04-04-gap-2 |
| #551 | SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency | SYK, TREM2 | 0.548 | $0.54 | SDA-2026-04-14-gap-p |
| #552 | Microglial TREM2-Independent Pathway Activation | DAP12, SYK, PLCG2 | 0.547 | $0.52 | SDA-2026-04-03-gap-d |
| #553 | CD300f Immune Checkpoint Activation | CD300F | 0.545 | $0.53 | SDA-2026-04-03-gap-a |
| #554 | Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling | SIRT1, FOXO3, NRF2, TFAM | 0.544 | $0.53 | SDA-2026-04-03-gap-c |
| #555 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.544 | $0.53 | SDA-2026-04-04-gap-t |
| #556 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | DNAJB6 | 0.544 | $0.51 | SDA-2026-04-01-gap-9 |
| #557 | Temporal Decoupling via Circadian Clock Reset | CLOCK | 0.543 | $0.58 | sda-2026-04-01-gap-0 |
| #558 | TREM2-GluN2B Circuit: Microglial Control of Thalamocortical Oscillations and Glymphatic Tau Clearance | TREM2 | 0.543 | $0.55 | SDA-2026-04-03-26abc |
| #559 | Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0021 in Early-Stage AD | CSF p-tau217 (biomarker), lncRNA-0021, astrocyte-derived extracellular vesicles | 0.542 | $0.56 | SDA-2026-04-26-gap-p |
| #560 | Astrocyte Metabolic Memory Reprogramming | SIRT1 | 0.541 | $0.53 | SDA-2026-04-04-gap-d |
| #561 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #562 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #563 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #564 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.48 | test-hypothesis-fixt |
| #565 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #566 | H6: Epigenetic Reset via APOE4→APOE3 Conversion Reverses Senescence | APOE; HDAC1; EZH2 | 0.540 | $0.53 | SDA-2026-04-06-gap-d |
| #567 | TAM Receptor (MERTK/AXL) Cross-Regulation | MERTK, AXL, TYRO3, PROS1 (Protein S), GAS6 | 0.540 | $0.53 | SDA-2026-04-06-gap-p |
| #568 | H5: Olfactory System as a Toxicant Funnel into Layer II | NLRP3, CX3CR1, TLR4 | 0.540 | $0.53 | SDA-2026-04-02-gap-e |
| #569 | Systemic IL-6–STAT3–Hepatic C3 Axis and BBB-Mediated Complement Translocation | IL6; STAT3; C3 | 0.540 | $0.53 | SDA-2026-04-08-gap-p |
| #570 | Soluble CX3CL1 cleavage by ADAM proteases disengages fractalkine signaling, removing the neuronal 'don't eat me' signal from microglial CX3CR1 | CX3CL1, CX3CR1, ADAM10, ADAM17 | 0.540 | $0.54 | SDA-2026-04-02-gap-s |
| #571 | P2Y6R activation by UDP from damaged neurons drives microglial phagocytosis and exosomal re-secretion in mid-to-late disease | P2RY6 | 0.540 | $0.53 | SDA-2026-04-07-gap-d |
| #572 | Dual-Phase Medium-Chain Triglyceride Intervention | HMGCS2/CPT1A | 0.540 | $0.52 | SDA-2026-04-04-gap-d |
| #573 | Microglial Exosome-Mediated Tau Propagation | MAPT | 0.539 | $0.54 | SDA-2026-04-03-26abc |
| #574 | Lysosomal Membrane Repair Enhancement | CHMP2B | 0.538 | $0.56 | sda-2026-04-01-gap-0 |
| #575 | ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling | ABCA7 + TREM2 (combinatorial) | 0.538 | $0.53 | SDA-2026-04-14-gap-p |
| #576 | Glymphatic System-Enhanced Antibody Clearance Reversal | AQP4 | 0.537 | $0.58 | sda-2026-04-01-gap-0 |
| #577 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.537 | $0.56 | test-hypothesis-fixt |
| #578 | CD36 Acts as Primary Aβ Oligomer Sensor on Perivascular Macrophages, Triggering NF-κB-Dependent SPP1 Transcription | SPP1 | 0.535 | $0.60 | SDA-2026-04-06-gap-p |
| #579 | NFκB/C1Q SASP Modulation for Synaptic Protection | C1Q | 0.534 | $0.53 | SDA-2026-04-26-gap-p |
| #580 | Blood-Brain Barrier SPM Shuttle System | TFRC | 0.533 | $0.57 | sda-2026-04-01-gap-0 |
| #581 | Gut Barrier Permeability-α-Synuclein Axis Modulation | CLDN1, OCLN, ZO1, MLCK | 0.533 | $0.53 | SDA-2026-04-01-gap-2 |
| #582 | Lactate/Pyruvate Ratio Dynamics in CSF as a Neuroinflammation-Metabolism Interface Biomarker | LDHA, TREM2 | 0.532 | $0.56 | SDA-2026-04-04-SDA-2 |
| #583 | PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction | PLCG2 | 0.532 | $0.54 | SDA-2026-04-01-gap-0 |
| #584 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.532 | $0.53 | sda-2026-04-12-ev-ad |
| #585 | Mitochondrial-Cytokine Axis Modulation | Mitochondrial respiratory complexes and inflammatory cytokine receptors | 0.532 | $0.52 | SDA-2026-04-03-gap-a |
| #586 | Cryptic Exon Silencing Restoration | TARDBP | 0.531 | $0.55 | sda-2026-04-01-gap-v |
| #587 | Modulating Tunneling Nanotube (TNT) Formation via M-Sec/Noradrenaline Signaling | TNFRSF12A (M-Sec) | 0.530 | $0.53 | SDA-2026-04-04-gap-t |
| #588 | C1Q-Angiogenic Axis Promoting Plaque Neovascularization | C1QA/C1QC | 0.530 | $0.53 | SDA-2026-04-07-gap-p |
| #589 | Therapeutic Repurposing: C1-INH as Plaque-Stabilizing Agent | C1R/C1S | 0.530 | $0.53 | SDA-2026-04-07-gap-p |
| #590 | CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial Priming Reversal | MIR155 (microRNA-155) | 0.530 | $0.53 | SDA-2026-04-08-gap-d |
| #591 | Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics | SLC16A2 | 0.529 | $0.55 | sda-2026-04-01-gap-0 |
| #592 | PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria | BNIP3/BNIP3L | 0.529 | $0.51 | SDA-2026-04-01-gap-2 |
| #593 | Lipid Nanoparticle Encapsulation of IGFBPL1-mRNA | IGFBPL1 | 0.527 | $0.53 | SDA-2026-04-06-gap-d |
| #594 | TREM2 Epigenetic Window for Microglial Lipid Metabolism | TREM2/HDAC1 | 0.525 | $0.53 | SDA-2026-04-07-gap-d |
| #595 | Pharmacogenomic CNS Drug Optimization Platform | CYP450 enzymes, transporters, and drug targets | 0.524 | $0.53 | SDA-2026-04-04-gap-d |
| #596 | TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance | TREM2 | 0.524 | $0.53 | SDA-2026-04-03-26abc |
| #597 | Circadian Clock Epigenetic Desynchronization Window | BMAL1/HDAC3 | 0.524 | $0.53 | SDA-2026-04-07-gap-d |
| #598 | C1q Binding to Specific Synaptic Proteomes via Neurexin/Neuroligin Complexes | NRXN1, NLGN1 (Neuroligin 1) | 0.522 | $0.52 | SDA-2026-04-07-gap-p |
| #599 | TREM2 Agonism to Redirect Microglia from Synaptic Pruning to OPTN-Deficient Neuron Protection | TREM2 | 0.521 | $0.53 | SDA-2026-04-14-gap-p |
| #600 | Restoring AQP4 Astrocyte Polarization Enhances Glymphatic Tau Clearance and Limits Template-Dependent Spreading | AQP4 | 0.520 | $0.52 | SDA-2026-04-04-gap-2 |
| #601 | Dysregulated microglial glycolysis via HIF1α activation shifts the balance from neuroprotective surveillance to complement-mediated synapse engulfment | HIF1A, LDHA, LDHB, PKM2, TREM2, AMPK/mTOR | 0.520 | $0.53 | SDA-2026-04-02-gap-s |
| #602 | Telomere Attrition and DNA Damage Response Activation Induces Microglial Senescence | TP53/CDKN2A/CDKN1A/ATM/ATR | 0.520 | $0.53 | SDA-2026-04-06-gap-p |
| #603 | Loss of Nuclear Lamin B1 Distinguishes Senescent Microglia from Inflammatory Activation | LMNB1 (Lamin B1) | 0.520 | $0.53 | SDA-2026-04-06-gap-d |
| #604 | GATA4 Stabilization and NF-κB Co-activation Identifies Senescent Microglia | GATA4, SQSTM1/p62, NFKB subunits | 0.520 | $0.53 | SDA-2026-04-06-gap-d |
| #605 | M-Sec/TNTA2-mediated tunneling nanotube formation drives glia-neuron tau propagation in mid-stages | TNFAIP2 | 0.520 | $0.53 | SDA-2026-04-07-gap-d |
| #606 | Mitochondrial DNA Damage and cGAS-STING Activation Induces Microglial Senescence | CGAS/STING1/TMEM173 | 0.520 | $0.53 | SDA-2026-04-06-gap-p |
| #607 | Severely Depleted mtDNA and Impaired OXPHOS Defines Senescent Microglia | MT-ND1, MT-CO1, TFAM, SIRT3 | 0.520 | $0.53 | SDA-2026-04-06-gap-d |
| #608 | TSPO PET Kinetic Modeling for Priming State Discrimination | TSPO | 0.520 | $0.51 | SDA-2026-04-06-gap-d |
| #609 | Piezoelectric Nanochannel BBB Disruption | CLDN5, OCLN | 0.519 | $0.53 | sda-2026-04-01-gap-0 |
| #610 | NRF2 Activation to Counteract Oxidative Stress from RGS6 Deficiency | - | 0.518 | $0.51 | SDA-2026-04-17-gap-p |
| #611 | Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Downregulation via NRF2 | NRF2/NFE2L2 | 0.517 | $0.53 | SDA-2026-04-07-gap-p |
| #612 | Hippocampus ages transcriptionally faster than cerebellum, defining a regional vulnerability axis conserved across species | CLU | 0.516 | $0.53 | aging-mouse-brain-20 |
| #613 | Vocal Cord Neuroplasticity Stimulation | CHR2/BDNF | 0.515 | $0.54 | sda-2026-04-01-gap-0 |
| #614 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.513 | $0.60 | sda-2026-04-12-ev-ad |
| #615 | GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease | GAS6/TAM receptor complex | 0.513 | $0.53 | SDA-2026-04-14-gap-p |
| #616 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.512 | $0.53 | test-hypothesis-fixt |
| #617 | Microbial Metabolite-Mediated α-Synuclein Disaggregation | SNCA, HSPA1A, DNMT1 | 0.511 | $0.52 | SDA-2026-04-01-gap-2 |
| #618 | Tripartite Synapse Cell Type-Nonautonomous Crosstalk: Coordinated Failure | C1Q | 0.510 | $0.52 | SDA-2026-04-02-gap-s |
| #619 | Primed microglia occupy a hybrid high-glycolysis and high-respiration metabolic state | PDHA1 | 0.510 | $0.52 | SDA-2026-04-07-gap-d |
| #620 | Blood Monocyte Epigenetic Signature as Surrogate for Microglial Priming | Epigenetic landscape (TLR4, NLRP3, IL1B regulatory regions) | 0.509 | $0.51 | SDA-2026-04-06-gap-d |
| #621 | Circulating IBA1 Protein Absorption/Interference with Detection | AIF1/IBA1 | 0.507 | $0.53 | SDA-2026-04-07-gap-p |
| #622 | Epigenetic Dysregulation of APOE Microglial Expression | APOE | 0.507 | $0.51 | SDA-2026-04-07-gap-d |
| #623 | PKM2 nuclear translocation bridges metabolism and inflammatory transcription in primed microglia | PKM2 | 0.506 | $0.52 | SDA-2026-04-07-gap-d |
| #624 | TYRO3-STAT1 Axis to Preserve Parvalbumin Interneuron Function by Suppressing IL-1β-Mediated Inflammatory Damage | TYRO3 | 0.506 | $0.53 | SDA-2026-04-14-gap-p |
| #625 | Synthetic Biology Approach: Designer Mitochondrial Export Systems | Synthetic fusion proteins | 0.505 | $0.51 | SDA-2026-04-01-gap-2 |
| #626 | Stage-Dependent Biphasic SPP1 Targeting: Early Enhancement Followed by Late Inhibition | SPP1 | 0.503 | $0.51 | SDA-2026-04-07-gap-p |
| #627 | APOE4 astrocytes fail to supply sufficient cholesterol to parvalbumin interneurons, causing presynaptic GABA release deficits, disinhibition, and network hyperexcitability characteristic of AD | LDLR, LRP8 (ApoER2), APOE | 0.500 | $0.52 | SDA-2026-04-04-gap-a |
| #628 | NETosis Amplification by C1Q in Plaque Neutrophils | C1QA/C1QC | 0.500 | $0.51 | SDA-2026-04-07-gap-p |
| #629 | Early Postnatal TGF-beta Signaling Establishes Lifelong Regional Vulnerability Through Irreversible Transcriptional Imprinting | TGFBR1 | 0.500 | $0.52 | SDA-2026-04-06-gap-p |
| #630 | Selectively Inhibit Maladaptive AQP4-Driven Astrocyte-Microglia Inflammatory Signaling in Parkinsonian Injury | AQP4, NFKB1, IL1B, TNF | 0.500 | $0.52 | SDA-2026-04-07-gap-p |
| #631 | SIRT1-Mediated Epigenetic Restoration of MFSD2A Expression Re-enables SPM Precursor Transport in Aged BBB | MFSD2A / SIRT1 (deacetylase activator axis) | 0.500 | $0.51 | SDA-2026-04-12-gap-d |
| #632 | Alectinib-C1q Complex Hijacks TREM2's Synaptic Protective Binding Interface | C1QA/C1QB/C1QC, TREM2 | 0.500 | $0.53 | SDA-2026-04-16-gap-p |
| #633 | TREM2-Mediated Microglial Dysfunction Drives Tau-Induced Blood-Brain Barrier Breakdown | TREM2 | 0.499 | $0.53 | SDA-2026-04-03-26abc |
| #634 | Conditional CRISPR Kill Switches for Aberrant Protein Clearance | UBE3A, PARK2, PINK1 | 0.496 | $0.60 | SDA-2026-04-03-gap-c |
| #635 | TREM2 on Perivascular Macrophages Senses Aβ and Drives SPP1 Upregulation Through CSF1R-Mediated Survival and Metabolic Signaling | SPP1 | 0.496 | $0.51 | SDA-2026-04-06-gap-p |
| #636 | Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhancement During Critical Neuroinflammatory Windows | NLRP3 | 0.496 | $0.52 | SDA-2026-04-15-gap-p |
| #637 | TREM2-Mediated Microglial Metabolic Reprogramming Accelerates Tau Pathological Spread | TREM2 | 0.494 | $0.53 | SDA-2026-04-03-26abc |
| #638 | YAP/TAZ Mechanosensing Cooperates with NF-κB to Amplify SPP1 Transcription in Perivascular Fibroblasts | SPP1 | 0.492 | $0.59 | SDA-2026-04-06-gap-p |
| #639 | GluN2B-Regulated Microglial Phagocytosis of Tau Aggregates via CX3CR1 Signaling | GRIN2B | 0.491 | $0.52 | SDA-2026-04-03-26abc |
| #640 | P2RY12/P2RY13 Purinergic Receptor Metabolic Rewiring | P2RY12, P2RY13, CTNNB1 (β-catenin), GSK3β | 0.490 | $0.51 | SDA-2026-04-06-gap-p |
| #641 | Testosterone-Derived DHT Amplifies Microglial Androgen Receptor Signaling Driving Male-Biased Neuroinflammation | AR | 0.490 | $0.51 | SDA-2026-04-06-gap-p |
| #642 | C1q-Mediated Delivery of miR-33 Antisense Oligonucleotides for Enhanced APOE4 Lipidation | miR-33a/miR-33b | 0.489 | $0.51 | SDA-2026-04-16-gap-d |
| #643 | APOE4 Structural Remodeling via HSP70 Chaperone Enhancement Strategy | HSP70/APOE4 | 0.486 | $0.51 | SDA-2026-04-16-gap-d |
| #644 | Oligodendrocyte Progenitor Cell Metabolic Reprogramming | PDK1, PFKFB3, LDHA | 0.486 | $0.57 | SDA-2026-04-03-gap-d |
| #645 | GluN2B-Mediated Perivascular Pericyte Control of Glymphatic Tau Clearance | GRIN2B | 0.485 | $0.52 | SDA-2026-04-03-26abc |
| #646 | TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation | TFEB | 0.485 | $0.50 | SDA-2026-04-03-gap-i |
| #647 | PINK1/PARK2-LC3 Mitophagy Enhancement | PINK1 | 0.485 | $0.50 | SDA-2026-04-03-gap-i |
| #648 | SIRT3 gates microglial surveillance versus primed metabolism through mitochondrial deacetylation | SIRT3 | 0.482 | $0.50 | SDA-2026-04-07-gap-d |
| #649 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery | RAB27A/LAMP2B | 0.482 | $0.47 | SDA-2026-04-01-gap-2 |
| #650 | ISG Threshold Model Explains Acute vs Chronic Neurodegeneration Outcomes | USP18 / JAK/STAT pathway | 0.480 | $0.51 | SDA-2026-04-07-gap-p |
| #651 | Enteric Nervous System Prion-Like Propagation Blockade | TLR4, SNCA | 0.480 | $0.48 | SDA-2026-04-01-gap-2 |
| #652 | CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping | CX3CR1 | 0.477 | $0.50 | SDA-2026-04-06-gap-d |
| #653 | Optogenetic Control of Mitochondrial Transfer Networks | ChR2 | 0.476 | $0.47 | SDA-2026-04-01-gap-2 |
| #654 | Ferroptosis as Context-Dependent and Motor Neuron-Subtype Selective | - | 0.475 | $0.52 | SDA-2026-04-18-gap-d |
| #655 | CD44-Mediated Src/PI3K/Akt Signaling Cascade | CD44, SRC, PI3K p85 (PIK3R1), MTOR | 0.470 | $0.50 | SDA-2026-04-06-gap-p |
| #656 | C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis | C1QA/C1QC | 0.470 | $0.50 | SDA-2026-04-07-gap-p |
| #657 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | PHB2 | 0.469 | $0.46 | SDA-2026-04-01-gap-9 |
| #658 | APOE and TREM2 interact to modulate age-dependent microglial dysfunction | TREM2 | 0.467 | $0.53 | aging-mouse-brain-20 |
| #659 | Cross-Tissue Communication Disruption | MULTIPLE | 0.466 | $0.51 | SDA-2026-04-16-gap-b |
| #660 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | TARDBP | 0.465 | $0.45 | SDA-2026-04-01-gap-9 |
| #661 | TYROBP Network Hyperactivation Marks Point of No Return | TYROBP/SYK axis, MAPK/ERK signaling | 0.463 | $0.49 | SDA-2026-04-06-gap-d |
| #662 | Microglial Priming Window for HDAC1-Dependent DAM Transition | HDAC1 | 0.463 | $0.50 | SDA-2026-04-07-gap-d |
| #663 | Necroptosis-cGAS Feedforward Loop Converts TDP-43 Pathology into Neuroinflammation | MLKL / RIPK1 | 0.460 | $0.50 | SDA-2026-04-07-gap-p |
| #664 | TSPO-Mediated TDP-43 Mitochondrial Import | TSPO (TSPO), TDP-43-TSPO protein-protein interaction | 0.460 | $0.50 | SDA-2026-04-07-gap-p |
| #665 | Selective Microglial Senescence Targeting via TREM2 Modulation | TREM2 | 0.459 | $0.52 | SDA-2026-04-04-gap-s |
| #666 | Astrocytic SPP1 Modulation via STAT3-Dependent Transcriptional Control | SPP1 | 0.459 | $0.00 | SDA-2026-04-15-gap-p |
| #667 | Intranasal IGFBPL1 Delivery via Olfactory Pathway | IGFBPL1 | 0.459 | $0.49 | SDA-2026-04-06-gap-d |
| #668 | Kinase Inhibitor-C1q Structural Convergence for Bifunctional Drug Design | C1QA/C1QB/C1QC, ALK, SYK | 0.458 | $0.54 | SDA-2026-04-16-gap-p |
| #669 | CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0021 in AD | CSF neurofilament light chain (NfL), lncRNA-0021, astrocyte-derived extracellular vesicles | 0.458 | $0.52 | SDA-2026-04-26-gap-p |
| #670 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuronal Cross-Talk Normalization | C1QA/C1QB/C1QC | 0.455 | $0.49 | SDA-2026-04-15-gap-p |
| #671 | Mitochondrial Damage-Triggered SPP1 Inflammasome Coupling | SPP1 | 0.453 | $0.50 | SDA-2026-04-15-gap-p |
| #672 | TREM2-SYK Signaling Axis Couples OxPC Recognition to Phagocytic Clearance | TREM2 (Triggering receptor expressed on myeloid cells 2) + SYK (spleen tyrosine kinase) | 0.453 | $0.51 | SDA-2026-04-13-gap-p |
| #673 | Astrocyte Heterogeneity and Synapse-Specific Eat-Me Signal Expression | MFGE8, NPTX2 (Neuronal Pentraxin 1) | 0.451 | $0.49 | SDA-2026-04-07-gap-p |
| #674 | α4β1 Integrin (VLA-4) and JAK/STAT Pathway | ITGA4, ITGB1 (α4β1 heterodimer), JAK1/JAK2, STAT3 | 0.450 | $0.49 | SDA-2026-04-06-gap-p |
| #675 | Astrocytic APOE4 Disruption of GABAergic Support Increasing Neuronal Vulnerability | SLC1A2 (GLT-1), GABRA1, GABRB3, GAD1 | 0.450 | $0.49 | SDA-2026-04-07-gap-p |
| #676 | Paraneoplastic myelopathies involve CD8+ T cell recognition of viral/cancer antigens causing necroptotic neuronal death | HLA-A, HLA-B, CD8A, CD8B, PRF1, GZMB, RIPK3, MLKL | 0.450 | $0.49 | SDA-2026-04-08-gap-p |
| #677 | CSF Neurofilament Light-Triggered Astrocyte-Derived Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD | CSF neurofilament light (biomarker), lncRNA-0021, astrocyte-derived exosomes | 0.450 | $0.51 | SDA-2026-04-26-gap-p |
| #678 | Astrocytic SPP1 Modulation for Neuroinflammatory Resolution | SPP1 | 0.447 | $0.50 | SDA-2026-04-15-gap-p |
| #679 | C1q-Alectinib Complexation Disrupts Tight Junction Integrity to Enable Paracellular Brain Penetration | CLDN5, OCLN | 0.445 | $0.49 | SDA-2026-04-17-gap-d |
| #680 | MITF Acts as the Primary Transcriptional Effector Downstream of HDAC1/2 Deletion, Driving the DAM2 Lysosomal Program Through De-repression of Phagocytic Enhancers | MITF | 0.444 | $0.50 | SDA-2026-04-13-gap-p |
| #681 | Microglial Membrane Camouflage Exploits CD47-SIRPα Checkpoint Disinhibition | CD47, SIRPA, PTPN6, PTPN11 | 0.444 | $0.50 | SDA-2026-04-16-gap-p |
| #682 | RAGE/STAT3/IL-6 Autocrine Loop Mediates Aβ-Induced SPP1 Upregulation in Perivascular Fibroblasts | SPP1 | 0.442 | $0.49 | SDA-2026-04-06-gap-p |
| #683 | Monocyte Trojan Horse Cell Therapy | IGFBPL1 | 0.441 | $0.49 | SDA-2026-04-06-gap-d |
| #684 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.437 | $0.49 | test-hypothesis-fixt |
| #685 | Blood-Brain Barrier Disruption Enabling Peripheral Inflammatory Insult | PDGFRB, CLDN5, OCLN, FGB | 0.430 | $0.49 | SDA-2026-04-07-gap-p |
| #686 | GSK3β Inhibition to Prevent α-Synuclein Phosphorylation and Aggregation | - | 0.429 | $0.47 | SDA-2026-04-17-gap-p |
| #687 | Source-Specific SPP1 Inhibition: Perivascular Cell Targeting | SPP1 (perivascular) | 0.429 | $0.48 | SDA-2026-04-07-gap-p |
| #688 | Microbiome-Derived Tryptophan Metabolite Neuroprotection | AHR, IL10, TGFB1 | 0.427 | $0.45 | SDA-2026-04-01-gap-2 |
| #689 | C1q-Targeted miR-33 ASO Delivery for APOE4 Hyper-Lipidation via Microglial Receptor-Mediated Transcytosis | miR-33a/miR-33b | 0.427 | $0.48 | SDA-2026-04-16-gap-d |
| #690 | Lactate-HCAR1 signaling maintains a self-reinforcing glycolytic priming loop | HCAR1 | 0.427 | $0.48 | SDA-2026-04-07-gap-d |
| #691 | C1q-Conjugated miR-33 ASO Brain Delivery for Enhanced APOE4 Lipidation | miR-33a/miR-33b | 0.423 | $0.48 | SDA-2026-04-16-gap-d |
| #692 | P2X7/P2Y12 Purinergic Signaling Connects Aβ Aggregation to SPP1 Transcription via Calcineurin/NFAT Pathway | SPP1 | 0.423 | $0.56 | SDA-2026-04-06-gap-p |
| #693 | Complement Cascade Activation Bridges Microglial OxPC Sensing to Synaptic Vulnerability | C1QA, C3, C3AR1 (complement cascade) | 0.419 | $0.50 | SDA-2026-04-13-gap-p |
| #694 | P2RY12-mediated cerebral VSMC dysfunction establishes a vicious cycle with microglial P2RY12 activation | P2RY12 (dual: VSMC + microglia) | 0.418 | $0.49 | SDA-2026-04-07-gap-p |
| #695 | HDAC2-Specific Repression of PU.1 Pioneer Factor Target Sites Suppresses the IL-33/ST2-Phagocytic Axis; HDAC2 Deletion Specifically Unmasks These Enhancers | HDAC2 | 0.415 | $0.51 | SDA-2026-04-13-gap-p |
| #696 | C1q-Alectinib Complexation Enhances CNS Penetration via Microglial C1qR-Mediated Uptake and Redistribution | C1QBP | 0.415 | $0.49 | SDA-2026-04-17-gap-d |
| #697 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.400 | $0.47 | test-hypothesis-fixt |
| #698 | LncRNA-HDAC1 Complex Formation Locks Microglia in Primed State | HDAC1/NEAT1 | 0.400 | $0.48 | SDA-2026-04-07-gap-d |
| #699 | IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability | IGFBPL1 | 0.397 | $0.51 | SDA-2026-04-06-gap-d |
| #700 | CSF1R Inhibition Reversal Window Depends on Microglia Replacement Kinetics | CSF1R, nestin+ progenitor pool | 0.395 | $0.47 | SDA-2026-04-06-gap-d |
| #701 | BMAL1-CLOCK regulation of miR-143/145 locks microglia into glycolytic priming | ARNTL | 0.389 | $0.47 | SDA-2026-04-07-gap-d |
| #702 | Bacterial Enzyme-Mediated Dopamine Precursor Synthesis | TH, AADC | 0.384 | $0.44 | SDA-2026-04-01-gap-2 |
| #703 | LRP1-Autophagy BBB Permeabilization for Antibody Transport | LRP1; ATG7; OPTN (autophagy pathway); CLDN5 (tight junctions) | 0.380 | $0.47 | SDA-2026-04-02-gap-b |
| #704 | P2RY12 activation induces cellular senescence in cerebral VSMCs, driving neurodegeneration via SASP secretion | P2RY12 | 0.373 | $0.47 | SDA-2026-04-07-gap-p |
| #705 | Ferroptosis as Epiphenomenon of Terminal Collapse | - | 0.363 | $0.47 | SDA-2026-04-18-gap-d |
| #706 | Age-related neuroinflammation mimics early Alzheimer's disease pathology | GFAP | 0.362 | $0.53 | aging-mouse-brain-20 |
| #707 | Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange | PANX1 | 0.361 | $0.44 | SDA-2026-04-01-gap-2 |
| #708 | Ferroptosis as Primary Driver of Motor Neuron Death | - | 0.339 | $0.46 | SDA-2026-04-18-gap-d |
| #709 | CHMP2B vs. CHMP2A Subunit Targeting Creates a Therapeutic Window in ESCRT-Dependent Tau Sorting | CHMP2B, CHMP2A, CHMP4B | 0.330 | $0.45 | SDA-2026-04-06-gap-d |
| #710 | Novel Hypothesis on Metabolic Dysregulation in Neurodegeneration | SLC16A1 (MCT1) | 0.330 | $0.39 | - |
| #711 | Partial Agonist/SPP1 Splice Variant Strategy: Splice-Switching Therapeutics | SPP1 splicing factors | 0.311 | $0.45 | SDA-2026-04-07-gap-p |
| #712 | [Archived Hypothesis] | - | 0.300 | $0.30 | legacy-pre-pipeline- |
| #713 | [Archived Hypothesis] | - | 0.300 | $0.30 | legacy-pre-pipeline- |
| #714 | C1q-Alectinib Complexation Facilitates Brain Penetration via Receptor-Mediated Transcytosis | C1Q | 0.161 | $0.42 | SDA-2026-04-17-gap-d |
| #715 | Direct C1q Binding Enables FcγR-Independent Complement Activation on Tumor Cells | C1Q | 0.148 | $0.42 | SDA-2026-04-17-gap-d |
| #716 | Human Serum Albumin-Mediated Displacement Creates False-Positive C1q Binding Signals | C1Q | 0.132 | $0.41 | SDA-2026-04-17-gap-d |
| #717 | C1q Binding Reflects Broader Kinase Inhibitor Promiscuity Rather Than Specific Complement Targeting | C1Q | 0.124 | $0.42 | SDA-2026-04-17-gap-d |
| #718 | Alectinib Binds Mitochondrial C1q-like Proteins (C1QDC1) Rather Than Circulating C1q | C1Q | 0.122 | $0.42 | SDA-2026-04-17-gap-d |
| #719 | C1q Binding Analysis Across ALK Inhibitor Chemical Series Would Resolve Specificity | C1Q | 0.115 | $0.43 | SDA-2026-04-17-gap-d |
| #720 | P2RX7-PANX1 Channel Blockade for Neuroinflammatory Cascade Interruption | - | 0.105 | $0.42 | SDA-NEUROINFLAM-BIOM |
| #721 | TREM2 Agonism with CX3CR1 Antagonism for Microglial Homeostasis | TREM2 | 0.105 | $0.41 | SDA-NEUROINFLAM-BIOM |
| #722 | CD300f Immunoglobulin Receptor as Neuroinflammatory Brake | - | 0.105 | $0.42 | SDA-NEUROINFLAM-BIOM |
| #723 | IL-33/ST2 Axis Augmentation for Synaptic Protection | - | 0.105 | $0.42 | SDA-NEUROINFLAM-BIOM |
| #724 | NLRP3 Inflammasome Suppression via Selective Caspase-1 Inhibition | - | 0.105 | $0.40 | SDA-NEUROINFLAM-BIOM |
| #725 | TYROBP Causal Network Inhibition for Microglial Repolarization | - | 0.105 | $0.42 | SDA-NEUROINFLAM-BIOM |
| #726 | Alectinib's Putative C1q Binding Derives from Hydrophobic Aggregation Rather Than Direct Protein-Protein Interaction | C1Q | 0.105 | $0.44 | SDA-2026-04-17-gap-d |